

WHO/DIL/LAB/99.1 Rev.2
Original :ENGLISH
Distr.:GENERAL



WORLD HEALTH ORGANIZATION

**USE OF ANTICOAGULANTS IN DIAGNOSTIC
LABORATORY INVESTIGATIONS**

2002

© World Health Organization

This document is not a formal publication of the World Health Organization (WHO), but all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced or translated, in part or in whole, but not for sale or for use in conjunction with commercial purposes.

The views expressed by named authors are solely the responsibility of those authors.

USE OF ANTICOAGULANTS IN DIAGNOSTIC LABORATORY INVESTIGATIONS

&

Stability of blood, plasma and serum samples

Contributors:

G. Banfi, Milan, Italy
K. Bauer, Vienna, Austria
W.Brand, Nümbrecht, Germany
M.Buchberger, Kremsmünster, Austria
A. Deom, Geneva, Switzerland
W.Ehret, Augsburg, Germany*
W.D. Engel, Mannheim, Germany
F. da Fonseca-Wollheim, Berlin, Germany*
C.G. Fraser, Dundee, Scotland
V.J. Friemert, Deisenhofen, Germany
S. Golf, Giessen, Germany
H.Gross, Hanau, Germany
W.G. Guder, München, Germany**
G. Gunzer, Clare, Ireland
P. Hagemann, Zürich, Switzerland
W. Heil, Wuppertal, Germany*
J. Henny, Nancy, France
R. Hinzmann, Krefeld, Germany
P. Hyltoft Persen, Odense, Denmark
G. Hoffmann, Grafrath, Germany
A. Kallner, Stockholm, Sweden
A. Karallus, Heidelberg, Germany

H. Kitta, Usingen, Germany
D. Klahr, Tuttlingen, Germany
D. Kolpe, Nümbrecht-Elsenroth, Germany
J. Kukuk, Limburg, Germany
T. Kunert-Latus, Leuven, Belgium
M.Lammers, Marburg, Germany
E.A. Leppänen, Helsinki, Finland
P. Mikulcik, Fernwald, Germany
S. Narayanan, New York, USA
M. Neumaier, Hamburg, Germany
M.A. Peça Amaral Gomes, Lisbon, Portugal
R. Probst, Munich, Germany
Y. Schmitt Darmstadt, Germany*
O. Sonntag, Neckargemünd, Germany
G. Töpfer, Görlitz, Germany*
R. Weisheit, Penzberg, Germany
H. Wisser, Stuttgart, Germany*
B. Zawta, Mannheim, Germany*
R. Zinck Mannheim, Germany

* Member of working group
** Chairman of working group

The WHO document "Use of Anticoagulants in Diagnostic Laboratory Investigations" (WHO/DIL/LAB/99.1 Rev. 1) received a surprising resonance and experts around the world provided many additional observations. This information has been included in the 2nd revision of the document. The document provides an extensive summary of observations on the effects of anticoagulants in blood, plasma and serum. Information on the effects of haemolysis, hyperbilirubinaemia and hyperlipoproteinaemia on measurement procedures has been added.

WHO is grateful for the efforts made by the group of experts in collecting all the information necessary for this revised version.

Geneva, 15 January 2002

Contents

| | | |
|----------|--|-----------|
| 1 | Serum, Plasma or Whole Blood? Which Anticoagulants to Use? | 5 |
| 1.1 | Definitions..... | 5 |
| 1.1.1 | Whole blood..... | 5 |
| 1.1.2 | Plasma | 5 |
| 1.1.3 | Serum..... | 5 |
| 1.1.4 | Anticoagulants | 5 |
| 1.2 | Plasma or serum?..... | 6 |
| 1.2.1 | Advantages of using plasma | 6 |
| 1.2.2 | Disadvantages of plasma over serum..... | 6 |
| 1.2.3 | Analytical samples in the serological diagnosis of infectious diseases | 7 |
| 1.3 | Recommendations..... | 7 |
| 1.3.1 | Sample collection and transport time | 7 |
| 1.3.2 | Centrifugation..... | 7 |
| 1.3.3 | Storage | 8 |
| 1.3.4 | Evaluation of new analytical procedures | 8 |
| 2 | The Optimal Sample Volume | 8 |
| 2.1 | Definition..... | 8 |
| 2.2 | Recommendations..... | 9 |
| 2.2.1 | Measures which can help to reduce the required blood volume | 9 |
| 2.2.2 | Documentation..... | 9 |
| 3 | Analyte Stability in Sample Matrix | 9 |
| 3.1 | Stability and Instability | 10 |
| 3.2 | Quality assurance of the time delay during the pre-analytical phase..... | 10 |
| 3.2.1 | Transport time | 10 |
| 3.2.2 | Pre-analytical time in the laboratory | 10 |
| 3.2.3 | Documentation..... | 10 |
| 3.2.4 | Actions to be taken when the maximum permissible pre-analytical times are exceeded | 10 |
| 4 | The Haemolytic, Icteric and Lipaemic Sample | 11 |
| 4.1 | Definition of a clinically relevant interference..... | 11 |
| 4.2 | General recommendations | 11 |
| 4.2.1 | Documentation of interferences | 11 |
| 4.2.2 | Detection of a potentially interfering property and handling of sample and request | 12 |
| 4.2.3 | Reporting results | 12 |
| 4.3 | The haemolytic sample and the effect of therapeutic haemoglobin derivatives | 12 |
| 4.3.1 | Haemolysis | 12 |
| 4.3.2 | Haemoglobin based oxygen carriers used as blood substitutes | 12 |

| | | |
|----------|--|-----------|
| 4.3.3 | Detection and measurement of haemoglobin in serum or plasma | 13 |
| 4.3.4 | Distinction between in-vivo haemolysis and in-vitro haemolysis | 13 |
| 4.3.5 | Mechanisms of interference by haemolysis | 13 |
| 4.3.6 | Means to avoid haemolysis and its interferences | 14 |
| 4.3.7 | Reaction upon the receipt of haemolytic samples | 14 |
| 4.4 | The Lipaemic Sample | 15 |
| 4.4.1 | Definition | 15 |
| 4.4.2 | Causes of lipaemia (turbidity)..... | 15 |
| 4.4.3 | Identification and quantification of lipaemia..... | 15 |
| 4.4.4 | Mechanisms of the interference by lipaemia on analytical methods | 15 |
| 4.4.5 | Means to avoid lipaemia and interferences caused by turbidity | 16 |
| 4.4.6 | Recommendation..... | 17 |
| 4.4.7 | Test of interference by lipaemia..... | 17 |
| 4.5 | The icteric sample | 17 |
| 4.5.1 | Appearance of different bilirubin species | 17 |
| 4.5.2 | Mechanisms of bilirubin interference | 17 |
| 4.5.3 | Detection and documentation of increased bilirubin concentrations in clinical samples | 18 |
| 4.5.4 | Prevention of bilirubin interference | 18 |
| 5 | Samples and Stability of Analytes | 20 |
| 5.1 | Blood | 21 |
| 5.2 | Urine | 46 |
| 5.3 | Cerebrospinal Fluid (CSF)..... | 50 |
| 6 | References | 51 |

1 Serum, Plasma or Whole Blood? Which Anticoagulants to Use?

It is imperative that the in-vivo state of a constituent remains unchanged after withdrawal from the body fluid of a patient to obtain a valid medical laboratory result. This may not always be possible when measuring extra-cellular and cellular components of blood. Platelets and coagulation factors are activated when blood vessels are punctured, and their activation continues in sample containers that do not contain anticoagulant.

Historically, serum was the preferred assay material for determining extracellular concentrations of constituents in blood. Today, plasma is preferred for many, but not all, laboratory investigations because the constituents in plasma are better reflecting the pathological situation of a patient than in serum. Some changes of constituents can be avoided by using anticoagulants. The types and concentrations of anticoagulants used in venous blood samples were defined in the international standard (86) in 1996. The standardized anticoagulants are now used to prepare standardized plasma samples for laboratory investigations throughout the world.

This document summarizes the findings published in the literature and those observed by the contributors on the use of anticoagulants. The overview was prepared in collaboration with experts from clinical diagnostic laboratories and the diagnostics industry (68, 71).

1.1 Definitions

1.1.1 Whole blood

A venous, arterial or capillary blood sample in which the concentrations and properties of cellular and extra-cellular constituents remain relatively unaltered when compared with their in-vivo state. Anticoagulation in-vitro stabilizes the constituents in a whole blood sample for a certain period of time.

1.1.2 Plasma

The virtually cell-free supernatant of blood containing anticoagulant obtained after centrifugation.

1.1.3 Serum

The undiluted, extracellular portion of blood after adequate coagulation is complete.

1.1.4 Anticoagulants

Additives that inhibit blood and/or plasma from clotting ensuring that the constituent to be measured is non-significantly changed prior to the analytical process. Anticoagulation occurs by binding calcium ions (EDTA, citrate) or by inhibiting thrombin activity (heparinates, hirudin). The following solid or liquid anticoagulants are mixed with blood immediately after sample collection:

1.1.4.1 EDTA

Salt of ethylene diamine tetraacetic acid. Dipotassium (K_2), tripotassium (K_3) (41) and disodium (Na_2) salts are used (86); concentrations: 1.2 to 2.0 mg/mL blood (4.1 to 6.8 mmol/L blood) based on anhydrous EDTA.

1.1.4.2 Citrate

Trisodium citrate with 0.100 to 0.136 mol/L citric acid. Buffered citrate with pH 5.5 to 5.6: 84 mmol/L trisodium citrate with 21 mmol/L citric acid. Differences were noticed between 3.2% and 3.8% (v/v) citrate when reporting results in INR (1, 145, 192, 210). WHO and NCCLS recommend 0.109 mol/L (3.2%) citric acid. The International Society for Thrombosis and Haemostasis (ISTH) recommends the use of Hepes buffered citrate for all investigations of haemostatic functions (114).

- a. A mixture of one part citrate with nine parts blood is recommended for coagulation tests (86, 136).
- b. One part citrate mixed with four parts blood is recommended to determine the erythrocyte sedimentation rate (86).

1.1.4.3. Heparinates

12 to 30 IU/mL of unfractionated sodium, lithium or ammonium salt of heparin with a molecular mass of 3 to 30 kD is recommended to obtain standardized heparinized plasma (86).

Calcium-titrated heparin at a concentration of 40 to 60 IU/mL blood (dry heparinisation) and 8 to 12 IU/mL blood (liquid heparinisation) is recommended for the determination of ionized calcium (22).

1.1.4.4. Hirudin

Hirudin is an antithrombin extracted from leeches or prepared by a genetic engineering process. Hirudin inhibits thrombin by forming a 1:1 hirudin-thrombin complex. Hirudin is used at a concentration of 10 mg/L (40).

The *colour codes* of anticoagulants described in ISO/DIS 6710 are:

EDTA = lavender/red;

citrate 9 + 1 = light blue/green;

citrate 4 + 1 = black/mauve;

heparinate = green/orange;

no additives (for serum) = red/white (86).

1.2 Plasma or serum?

1.2.1 Advantages of using plasma

The following aspects support the preferential use of plasma versus serum in laboratory medicine:

Time saving: Plasma samples can be centrifuged directly after sample collection, unlike serum, in which coagulation is completed after 30 minutes,

Higher yield: 15 to 20 % more in volume of plasma than of serum can be isolated from the same volume of blood.

Prevention of coagulation-induced interferences: Coagulation in primary and secondary tubes that were already centrifuged, may block suction needles of the analyzers when serum tubes are used; this is prevented by using anticoagulants.

Prevention of coagulation-induced interferences: The coagulation process changes the concentrations of numerous constituents of the extra-cellular fluid beyond their maximum allowable limit (70, 202). The changes are induced by the following mechanisms:

- a. Increase in the concentrations of platelet components in serum as compared to plasma (e.g. potassium, phosphate, magnesium, aspartate aminotransferase, lactate dehydrogenase, serotonin, neurone-specific enolase, zinc). Release of amide-NH₃ from fibrinogen induced by action of clotting factor XIII.
- b. Decrease in the concentration of constituents in serum as a result of cellular metabolism and the coagulation process (glucose, total protein, platelets).
- c. Activation of the cell lysis of erythrocytes and leukocytes in non-coagulated blood (cell-free haemoglobin, cytokines, receptors).

Certain constituents should only be measured in plasma (e.g. neurone-specific enolase, serotonin, ammonia) to obtain clinically relevant results.

1.2.2 Disadvantages of plasma over serum

The addition of anticoagulants may interfere with certain analytical methods or change the concentration of the constituents to be measured:

- a. Contamination with cations: NH₄⁺, Li⁺, Na⁺, K⁺.

- b. Assay interference caused by metals complexing with EDTA and citrate (e.g. inhibition of alkaline phosphatase activity by zinc binding, inhibition of metallo-proteinases, inhibition of metal-dependent cell activation in function tests, binding of calcium (ionized) to heparin (22)).
- c. Interference by fibrinogen in heterogeneous immunoassays (202).
- d. Inhibition of metabolic or catalytic reactions by heparin: e.g., Taq polymerase in the polymerase chain reaction (PCR) (137).
- e. Interference in the distribution of ions between the intracellular and extracellular space (e.g. Cl^- , NH_4^+) by EDTA, citrate (70).
- f. Serum electrophoresis can be performed only after pre-treatment to induce coagulation in plasma.

1.2.3 Analytical samples in the serological diagnosis of infectious diseases

A variety of methods are used for serological diagnosis of infectious diseases. They include immuno-diffusion, immuno-precipitation, counter immuno-electrophoresis, agglutination of bacteria, haemagglutination and agglutination inhibition, particle-enhanced agglutination, complement fixation, indirect immuno-fluorescence (IFA), enzyme-linked immunoassay (ELISA), radio-immunoassay (RIA), neutralisation of toxins or virus-activity, immunoblot (Western blot) and others.

In general, serum is used for the serological diagnosis of infectious diseases; serum must be used for certain immunological techniques such as complement fixation or bacterial agglutination tests; for other tests, including some haemagglutination tests, ELISAs or immunoblots, either serum or plasma may be used.

1.3 Recommendations

Table 5.1 indicates materials that are recommended for a specific test. The table also contains information on the utility of other sample materials as long as the results measured by that method do not exceed the maximum allowable deviation of measurement (152) as defined by the biological variation (153). A maximum deviation of 10% is acceptable for a constituent if it is not included in the list.

1.3.1 Sample collection and transport time

The following sequence for filling tubes with blood from a patient is recommended to avoid contamination (70):

- blood for blood culture,
- serum [avoid serum as first tube when electrolytes shall be measured (116)],
- citrate, heparinate, EDTA containing tubes,
- tubes containing additional stabilizers (e.g. glycolytic inhibitors).

Only the recommended quantity of anticoagulant should be added, wherever required, to avoid errors in results.

Tilt the tube repeatedly (do not shake and avoid foaming) immediately after filling to mix the sample thoroughly with the anticoagulant. Leave the containers at room temperature for at least 30 minutes to separate serum from blood cells in blood that was taken from non-anticoagulated patients. This period is shorter when coagulation has been activated. Leave the sample at room temperature no longer than the period indicated in the table [see 5.1, (66)].

1.3.2 Centrifugation

Blood cells are rapidly separated from plasma/serum by centrifugation at increased relative centrifugal force (rcf). Rcf and rotations per minute (rpm) are calculated using the rotating radius r (the distance between the axis of rotation and the base of the container in mm) by the following equation:

$$\text{rcf} = 1,118 \times r (\text{rpm}/1000)^2$$

Centrifuge blood containers in 90°-swing-out rotors that the sediment surface forms a right angle with the container wall. This helps to prevent contact between the sampling needle and the surface of the cell layer or separating gel in the tube, when the centrifuged blood containers are directly transferred to an autoanalyzer for analysis.

1.3.2.1. Plasma

Centrifuge the anticoagulated blood (citrate, EDTA or heparinized blood) for at least 15 minutes at 2000 to 3000 g to obtain cell-free plasma.

1.3.2.2. Serum

When plasma coagulation is complete, centrifuge the sample for at least 10 minutes at a minimum speed of 1500 g.

When separating serum or plasma, the temperature should not drop below 15 °C or exceed 24 °C.

1.3.3 Storage

Non-centrifuged samples should be stored at room temperature for the time specified in the recommendations for stability [see table 5.1(66)]. After centrifugation, the serum or plasma should be analyzed within the time as recommended for whole blood, if the sample is stored without using a separating gel or a filter separator in primary tubes. When the sample shall be refrigerated or frozen for preservation, blood cells must first be separated from serum or plasma. Do not freeze whole blood samples before or after centrifugation, even when polymer separating gels are used.

1.3.4 Evaluation of new analytical procedures

Before using a new reagent or method, examine the suitability of the procedure by comparing the results of at least 20 blood samples with normal, and 20 with pathological concentrations of the constituent to be measured. The criteria for biological and clinical interpretation (reference intervals, clinical decision limits) may have to be changed, if the mean of the difference between the samples tested deviates by more than the maximum deviation allowed (152) (alternatively by more than 10 %).

2 The Optimal Sample Volume

The progress in the development of laboratory analyzers has led to a reduction of the sample volume for analysis. The development, however, is not necessarily accompanied by an adaptation of sample tubes and therefore often excessive sample volumes are collected. Studies revealed (30) that 208 mL blood for 42 tests is taken during an average stay of a patient in a department of internal medicine. In intensive care the total volume drawn for 125 tests was 550 mL of blood. Previous publications describe that in half of the patients who received blood transfusion, more than 180 mL of blood were taken for laboratory tests (174). "Iatrogenic anaemia" caused by excessive blood sampling is a well-known phenomenon in paediatrics (27), whereas iatrogenic anaemia is hardly recognized as an important phenomenon in the acute and intensive care of adult patients. The following recommendations were made for sampling reduced blood volumes for analysis (67):

2.1 Definition

The amount of sample needed for laboratory diagnostic purposes (Vol b) is defined by:

1. The analytical sample volume (Vol a),
2. The dead-space volume of the analyser (Da), measured as mL plasma/serum,
3. The dead-space volume of the primary sample tube (Dp), measured as mL blood,
4. The dead-space volume of secondary sample tubes (Ds), measured as mL plasma/serum,
5. The amount of sample needed for number (N) repetitive analysis and additional follow-up tests,
6. The plasma sample yield according to the respective haematocrit.

Assuming that plasma/serum yield is 50 % of blood volume the total blood needed can be calculated as follows:

$$Vol b = 2x [N x (Vol a + Da) + Ds] + Dp$$

2.2 Recommendations

Assuming a haematocrit of 0.50 and a need for a repetition and follow-up of laboratory tests, four times the analytical sample volume can be considered to be sufficient when plasma or serum shall be used. The following standard blood volumes are recommended for analysis using advanced analytical systems. These volumes may be sufficient in 95 % of cases to provide the laboratory results as requested:

- Clinical chemistry: 4 – 5 mL (when using heparin plasma: 3 – 4 mL)
- Haematology: 2 – 3 mL EDTA blood
- Coagulation tests: 2 – 3 mL citrated blood
- Immunoassays including proteins etc: 1 mL whole blood for 3 – 4 immunoassays
- Erythrocyte sedimentation rate: 2 – 3 mL citrated blood
- Blood gases, capillary sampling: 50 µl, arterial and venous sampling: 1 mL heparin blood

The request form for laboratory analyses should include clear information on the required sample volumes and tubes. Tubes of uniform size (for instance 4 – 5 mL tubes) with different filling volumes should be used. The length of the tubes should be at least four times the tube diameter. The criteria are met by standard tubes of 13 x 75 mm (diameter x length).

2.2.1 Measures which can help to reduce the required blood volume

- Introduction of primary tube reading in analyzers
- Deletion of sample distribution into secondary tubes
- Use of tubes with smaller diameter
- Use of analyzers requiring a smaller analytical sample volume
- Storage of samples in primary tubes, using separators for plasma or serum
- Use of plasma instead of serum

2.2.2 Documentation

1. Any method description should include the required analytical sample volume.
2. A quality manual should document the requested sample volumes and their handling procedure.
3. The manual should describe the procedures how to handle patient samples that have an insufficient sample volume.

3 Analyte Stability in Sample Matrix

The aim of a quantitative laboratory investigation is to determine the concentration or activity of a diagnostically relevant analyte in a body fluid in order to provide information on the clinical situation of a patient. This implies that the composition of the samples for analysis must not change during the pre-analytical phase (sampling, transportation, storage, sample preparation; 70).

3.1 Stability and Instability

Stability is the capability of a sample material to retain the initial property of a measured constituent for a period of time within specified limits when the sample is stored under defined conditions (87).

The measure of the instability is described as an absolute difference, as a quotient or as a percentage deviation of results obtained from measurement at time 0 and after a given period of time.

Example:

The transportation of whole blood for 3 to 4 hours at room temperature rises the concentration of potassium from 4.2 mmol/L to 4.6 mmol/L.

Absolute difference: 0.4 mmol/L

Quotient: 1.095

Percent deviation: + 9.5 %

The maximum permissible instability is the deviation of a result that corresponds to the maximum permissible relative imprecision of the measurement. This was defined as 1/12th of the biological reference interval (152). The deviation should be smaller than half of the total error derived from the sum of biological and technical variability (153). The stability of a blood sample during the pre-analytical phase is defined by the temperature, the mechanical load in addition to other factors. As time has also a major influence, the stability is stated as the maximum permissible storage time under defined conditions.

The maximum permissible storage time is the period of time at which the stability requirement of 95 % of the samples is met. This is a minimum requirement, since under pathological conditions the stability of an constituent in the sample can be considerably reduced (See examples in Table 5.1).

The storage time is stated in suitable units of time (days, hours, minutes). A clear distinction must be made between the storage of the primary sample (blood, urine, cerebrospinal fluid) and the storage of the analytical sample (e.g. plasma, serum, sediment, blood smear). The storage times are adopted for:

1. Storage of the primary sample at room temperature (20 to 25 °C)
2. Storage of the analytical sample at room temperature (20 to 25 °C), refrigerator temperature (4 to 8 °C) and deep-frozen (-20 °C).

3.2 Quality assurance of the time delay during the pre-analytical phase

3.2.1 Transport time

The transport time is the difference between the blood sampling time (in general with an accuracy of at least a quarter of an hour) and the registration time of the request and/or the arrival of the sample at the laboratory. The transportation time should be documented for each sample by the laboratory.

3.2.2 Pre-analytical time in the laboratory

The pre-analytical time in the laboratory is the difference between the time of analysis and the registration time of the sample. When the time at the end of the analytical phase (i.e. printing time of the result) is noted, the analysis time stated in the description of the method must be subtracted.

3.2.3 Documentation

It is recommended to state the sampling time and the arrival time of the sample in the laboratory in the report for the documentation of the transport time.

3.2.4 Actions to be taken when the maximum permissible pre-analytical times are exceeded

A medically relevant change of the results must be considered, when the maximum permissible transport and pre-analytical time of the sample was exceeded. The laboratory has the responsibility to mark the results of such samples with a note in the report, or to refuse to carry out the test. The latter

decision is advisable, when medical conclusions may be derived from the result that may be detrimental to the patient. The following example illustrates the problem:

An EDTA blood sample shows a rise in monocyte number from 4 to 10 % after four hours of storage measured by an automatic cell counter system. When this results is reported without comment, it could lead to an erroneous medical diagnosis that the patient suffers from a viral infection. Therefore, the clinician should be informed with a comment or a refusal, such as:

Comment: "The monocyte count may give incorrectly high values with the method used in our laboratory when EDTA blood is stored more than 2 hours. A control in the smear resulted in normal monocyte counts."

Refusal: "The maximum permissible transportation time was exceeded. Therefore the monocyte results are not stated, because they cannot correctly be determined. For the determination of correct monocyte counts, a transportation time of maximally two hours is acceptable."

4 The Haemolytic, Icteric and Lipaemic Sample

Medical laboratory tests are affected by endogenous and exogenous factors in the sample matrix. Certain potentially interfering factors may be recognized by a coloured appearance of the sample, whereas other factors (e.g. drugs) are detected only by additional information and/or direct analysis. Reference books provide useful information on drug interferences in laboratory analysis (178, 194, 214). Publications of standard setting organizations describe the methodology and statistical methods for the recognition and quantitative estimation of interferences in clinical chemical investigations (52, 135).

It is difficult to predict the effects of haemolysis, turbidity (lipaemia) and bilirubin (icterus), especially when reagents and analytical systems undergo modification (58,59). This document provides information that the laboratory can consider appropriate actions to ensure that the results of measurement are clinically relevant.

4.1 Definition of a clinically relevant interference

The maximal allowable deviation (bias) is expressed in % deviation of the result without interference as determined by a reference method. A clinically relevant bias should be considered if the change of the result caused by the interfering substance is more than the maximal allowable deviation of the analytical procedure (152). The bias usually amounts to 1/12 (which is about 8%) of the reference interval.

Data on the biological variability were published to define the medical needs. The desirable bias (B) derived from intra-individual (CV_w) and inter-individual (CV_b) variation was established for 316 analytes (153).

Example:

A result for plasma creatinine of 125 $\mu\text{mol/L}$ (1.41 mg/dL) was measured in an icteric sample by a routine method, whereas a creatinine concentration of 90 $\mu\text{mol/L}$ (1.02 mg/dL) was measured in the same sample by a reference method. For creatinine the maximum allowable deviation amounts to 9 % (158), the specification for B to 3.4 % (153). The result deviates by 35 $\mu\text{mol/L}$, which is 39 % from the expected value. Both criteria confirm that hyperbilirubinaemia is a clinically relevant interference when creatinine is measured using the routine method established in the laboratory.

4.2 General recommendations

4.2.1 Documentation of interferences

Documentation of method: Each clinical laboratory should specify the constituents in the quality manual that are affected by any of the following properties of the sample. The limits, beyond which the analysis shall not be performed, should be stated for each method that is subject to an interference. The

European Directive for In Vitro-Diagnostics (IVD) states that providers of reagents must define the appropriate limiting conditions (42). The procedure for the detection of interfering properties as well as actions that should be taken with the sample, should be documented in the quality manual.

4.2.2 Detection of a potentially interfering property and handling of sample and request

Each sample must be visually examined immediately after arrival or (in case of blood samples) after centrifugation and the potential interfering property recorded in the laboratory journal and report. When no visible interference is observed, it should be registered in the list by the notation: “appearance unremarkable”.

The requests should be reviewed to identify analytes that could be affected by the observed interference in the sample. Analytes that are not affected by the interference in the sample, are measured like in samples that contain no interference using the routine method of analysis. A sample that may be expectedly affected by an identified interference, must be pre-treated to eliminate the interference before measurement is made; alternatively a measurement method may be used that is not subject to the interference. The analysis should not be made when a clinically relevant bias is expected, or if the interference cannot be eliminated or circumvented by an appropriate alternative method.

4.2.3 Reporting results

Each report should include a notation characterising the samples' “appearance”. The observation should be documented for each sample: e.g. “haemolytic”, “icteric”, “opaescent”, “turbid”, or “lipaemic”, if a relevant colour or turbidity was identified.

The report should indicate, that the analysis was made despite a remarkable appearance of an interference in the sample. The report should also indicate when the sample was pre-treated prior to the analysis. If the interference in a sample cannot be eliminated for a subsequent analysis, the text “impaired by...” should replace the report of the result.

4.3 The haemolytic sample and the effect of therapeutic haemoglobin derivatives

4.3.1 Haemolysis

Haemolysis is defined as the release of intracellular components of erythrocytes and other blood cells into the extracellular space of blood (65). Haemolysis can occur in-vivo (e.g. through a transfusion reaction or during malaria parasite infection affecting the invaded erythrocytes), and in-vitro during all steps of the pre-analytical phase (sampling, sample transport and storage).

Haemolysis is caused by biochemical, immunological, physical and chemical mechanisms (18, 65). During blood transfusion, complement-dependent haemolysis may be caused by antibodies reacting with the major blood group antigens. Physical haemolysis is caused by destruction of erythrocytes by hypotonicity (e.g. dilution of blood with hypotonic solution), as well as decreased (vacuum) or increased pressure. Mechanical haemolysis may occur during the flow of blood through medical devices (e.g. catheters, heart valves) in-vivo, during inadequate centrifugation as well as at elevated temperature in-vitro. Contaminating substances may also cause in-vitro haemolysis. Finally, detergents (residual cleaning agents and disinfectants) and other contaminating substances may cause haemolysis.

After the separation of blood cells, haemolysis may be visible by the red colour of serum or plasma. The sample may concomitantly be contaminated by constituents of other blood cells (leukocytes and platelets). For example, cell breakdown may result in changes in blood of patients with leukaemia; the disintegration of platelets during coagulation results in higher concentrations of intracellular platelet constituents in serum (70). On the other hand, the intracellular components of erythrocytes are also released into plasma without a concomitant increase in haemoglobin concentration during storage of whole blood in refrigerators.

4.3.2 Haemoglobin based oxygen carriers used as blood substitutes

Therapeutic haemoglobin derivatives (so-called HbOC = haemoglobin-based oxygen carriers) were recently developed as blood substitutes. The substitutes occur at concentrations of up to 50 g/L in

plasma of patients under blood substitute treatment. Plasma or serum containing blood substitutes has a strong red colour (24, 92, 211).

4.3.3 Detection and measurement of haemoglobin in serum or plasma

4.3.3.1. Visual detection

At extracellular haemoglobin concentrations above 300 mg/L (18.8 mmol/L), haemolysis is detectable by the red colour of serum or plasma. Samples with therapeutic haemoglobin derivatives (in therapeutically effective concentration) are always intensely red coloured.

4.3.3.2. Spectrophotometric detection

Some analytical systems measure the extent of haemolysis by comparing the absorption of samples at two wavelengths (61). The absorption spectrum of the haemoglobin derived oxygen carriers used as blood substitutes does not differ substantially from that of natural haemoglobin.

4.3.3.3. Analytical measurement

Haemoglobin in plasma or serum is measured at concentrations that are below the concentration visible to the human eye (13, 110, 188).

4.3.4 Distinction between in-vivo haemolysis and in-vitro haemolysis

In-vivo haemolysis may be distinguished from in-vitro haemolysis by comparing a haemolytic sample of a patient with other samples from the same patient, arriving at the same time.

4.3.4.1. In-vivo haemolysis

Free haemoglobin in-vivo rapidly binds to haptoglobin and the complex is eliminated from the circulating blood (as in haemolytic anaemia). Consequently, haptoglobin is reduced during intra-vascular haemolytic process. The measurement of low concentration of haptoglobin thus permits an imperative assessment of haemolysis (exceptions are inborn haptoglobin deficiency and newborn children (199)). Likewise, the measurement of haemopexin and/or methaemoglobin/albumin was used to characterize in-vivo haemolysis (199).

A rise in concentration of indirect bilirubin and reticulocyte counts is a typical sign of in-vivo haemolysis, which in turn leads to increased erythropoiesis. Other consequences of in-vivo haemolysis, such as a change in the LDH iso-enzyme pattern, seem less suitable for the identification of haemolysis because of their low diagnostic sensitivity and specificity.

4.3.4.2. In-vitro haemolysis

After in-vitro haemolysis all constituents of erythrocytes, including potassium concentration, lactate dehydrogenase and aspartate aminotransferase activities, increase in addition to the concentration of free haemoglobin in plasma or serum (208). In contrast, haptoglobin concentration in plasma/serum of haemolytic samples remains unchanged. Certain immunological methods differ in their ability to distinguish haemoglobin/haptoglobin complexes from free haptoglobin (199).

4.3.4.3. Identification of haemoglobin derived oxygen carriers

Therapeutic haemoglobin derivatives yield a visible haemoglobin concentration within the range of 10 - 50 g/L. The absorption spectrum of haemoglobin derived oxygen carriers is not distinguishable from that of haemoglobin (24, 92, 211). However, haemoglobin concentrations of this magnitude rarely occur in vivo; therefore the use of therapeutic haemoglobin derivatives must be suspected at this plasma haemoglobin concentration. Haptoglobin cannot be used for discrimination, since the oxygen carriers form complexes with haptoglobin only slowly.

4.3.5 Mechanisms of interference by haemolysis

Haemolysis in-vivo or in-vitro can cause an apparent decrease or increase of results. A variety of mechanisms are contributing to these effects, some of which are summarized below:

4.3.5.1. Rise of intracellular constituents in the extra-cellular space

Cell constituents with an intracellular concentration 10 times higher than the extra-cellular concentration will increase in plasma/serum during haemolysis (e.g. potassium, lactate dehydrogenase,

aspartate aminotransferase). Differences of analyte concentrations between plasma and serum are also due to lysis of blood cells (essentially by platelets): Thus, neurone-specific enolase, potassium and acid phosphatase are higher in serum.

4.3.5.2. *Interference with analytical procedure*

Blood cell constituents can directly or indirectly interfere in the measurement of analytes. Adenylate kinase released from erythrocytes causes an increase of creatine kinase and CK-MB activity especially when inhibitors of adenylate kinase in the assay mixture are inadequate (182). In contrast, adenylate kinase does not affect the immunochemical quantification of CK-MB. Pseudo-peroxidase activity of free haemoglobin interferes in the bilirubin procedure of Jendrassik and Groof by inhibiting the diazonium colour formation (198). Proteases released from blood cells reduce the activity of coagulation factors while fibrin split product formation may increase.

4.3.5.3. *Optical interference by haemoglobin*

The effect of haemolysis on various analytes measured in clinical chemistry has been thoroughly investigated (18, 58, 176). Most often, the colour of haemoglobin increases the absorption at a respective wavelength or changes the blank value. An apparent increase or decrease of a result by haemoglobin is therefore method- and analyte concentration-dependent. Likewise, the changes caused by therapeutic haemoglobin derivatives are primarily due to optical interference (24, 92, 211).

4.3.6 Means to avoid haemolysis and its interferences

Haemolysis in-vitro can almost always be avoided, when the mechanism of haemolysis is known. Therefore each haemolytic sample should be documented and the cause of haemolysis identified.

The most frequent causes of haemolysis, such as errors during sampling, are avoided using standardized materials and methods for the pre-analytical processes and by training and individual counselling.

Sometimes reliable results can only be obtained from a truly non-haemolytic sample. In some cases, the interference can be reduced or excluded using a method that is not sensitive to haemolysis or by pre-treatment of the sample. Procedures, including de-proteinisation or molecular sieving (51) and others have not found to be useful, because of the work load involved. Today, a modification of the methodology, e.g. by using a blanking procedure by means of measurement at a second, appropriate wavelength, is preferred; although, this procedure may not be applicable for the analysis of blood from patients who received blood substitutes (59). Likewise the ultrafiltration procedure, as applied in the multi-layer film technology, reduces the effect of interference by haemolysis (178).

4.3.7 Reaction upon the receipt of haemolytic samples

Each laboratory should document the procedures that are affected by haemolysis and to what extent they are affected. The procedures how to handle haemolytic samples should be described in the quality manual. This includes the criteria for rejecting the execution of analysis.

The haemolysis of each sample must be documented and reported to the clinician who ordered the analysis.

When haemolysis occurs in all samples of a patient, haemolysis in-vivo may be suspected. This must be immediately reported to the clinician to verify the possible causes of haemolysis or the possible use of synthetic haemoglobin derivatives.

After estimation of the degree of haemolysis the sample is treated for analysis according to the degree of interference. The results of measurement may be reported as follows:

- Method not impaired: Report results as with non-haemolysed samples.
- Method impaired, but eliminated by pre-treatment: Report results after pre-treatment.
- Method impaired in a clinically relevant way: Instead of providing a result, report: "Impaired by haemolysis".

It is not recommended to correct a measured result for haemolysis arithmetically using the haemoglobin concentration as an indicator.

4.4 The Lipaemic Sample

4.4.1 Definition

Lipaemia is a turbidity of serum or plasma which is caused by elevated lipoprotein concentrations and which is visible by the eye. A sufficiently transparent sample container is a prerequisite to detect lipaemia. Visible detection of lipaemia is also dependent on the type of plasma lipoproteins at elevated concentrations in the sample. Post-centrifugal coagulation of serum samples of heparinized patients can also be the cause of turbidity.

4.4.2 Causes of lipaemia (turbidity)

Most often, lipaemia results from increased triglyceride concentration in plasma/serum. This can be due to food intake, altered lipid metabolism or infusion of lipids. After intestinal absorption, triglycerides are present in plasma as chylomicrons and their metabolites (remnants) for 6 to 12 h.

One to four hours after intake of a "Continental" or "American" breakfast, plasma triglyceride concentrations increase substantially. As they cause turbidity of the sample, the patient should be requested to fast, before investigations are made that are affected by lipaemia.

Metabolic disorders causing hypertriglyceridemia can hardly be distinguished from lipid infusions, cold agglutinins and monoclonal immunoglobulins.

4.4.3 Identification and quantification of lipaemia

4.4.3.1. *Optical and photometric methods for serum and plasma samples*

In whole blood triglyceride concentrations above 1000 mg/dL (11.3 mmol/L) cause turbidity that is detected by visual inspection. Lipaemia in plasma or serum is visually observed at triglyceride concentrations above 300 mg/dL (> 3.4 mmol/L). The extent of turbidity of serum/plasma samples is measured at wavelengths above 600 nm (e.g. 660/700 nm) (178).

4.4.3.2. *Detection in EDTA-blood*

Haematological tests are influenced by lipaemia. Thus, haemoglobin concentration is apparently increased by light scattering. The turbidity is detected by spectrophotometric analysis. The result of a centrifuged sample from the same patient taken at the same time can be used for comparison.

4.4.4 Mechanisms of the interference by lipaemia on analytical methods

4.4.4.1. *Interferences in spectrophotometric analysis*

Lipaemia interferes in photometric measurement by light scattering and light absorption. The apparent result can be either increased or reduced depending on the blanking procedure. At high turbidity, no measurement may be possible due to the limits of the linearity of the method (8).

4.4.4.2. *Volume depletion effect*

Lipoproteins decrease the apparent concentration of the analyte by reducing the available water of sample volume, since the volume occupied by lipoproteins in plasma or serum is included in the calculation of the analyte concentration. This explains why lower sodium and potassium concentrations are found in lipaemic sera, when plasma or serum is measured by flame photometry and by indirect measurement using ion-sensitive electrodes, in contrast to direct potentiometry (107). The same observation is made after centrifugation, when the lipoproteins are not homogeneously distributed in serum/plasma samples: the concentration of an analyte dissolved in the aqueous phase is less in the upper layer than in the lower phase of the sample. The converse is true for concentration of lipids and lipid soluble constituents, including certain drugs that are taken up by lipoproteins.

4.4.4.3. *Interference by physico-chemical mechanisms*

A constituent that is extracted by lipoproteins may not be accessible for the reagent, such as an antibody, for detection. Similarly, electrophoretic and chromatographic procedures may be affected by lipoproteins present in the matrix.

4.4.5 Means to avoid lipaemia and interferences caused by turbidity

To avoid interference of lipoproteins on measurement after oral intake of fat, the patient should fast at least 12 hours before blood samples are taken (186). In patients receiving parenteral infusion of lipids a period of 8 hours of interruption of the treatment is necessary to avoid interfering turbidity (70). If these measures do not provide a non-turbid sample, other causes of turbidity should be suspected.

Several methods were recommended to remove lipids from serum or plasma, such as centrifugation, to produce a clear infranatant sample. Other methods include the extraction of lipids with organic solvents or fluorine chlorinated hydrocarbons (e.g. Frigen[®]) and the precipitation of triglyceride-rich lipoproteins by polyanion and cyclodextrin (169).

4.4.5.1. Centrifugation

Centrifugation at 1000 g is effective, when chylomicrons cause turbidity. In contrast, at least 10 min, centrifugation at 12 000 g separates serum or plasma lipids by flotation.

The clear infranatant must be carefully separated for analysis. Ultra-centrifugation must be employed for the separation of low density lipoproteins and high density lipoproteins. A centrifugation time of at least 30 min at a speed above 40 000 g is recommended. The separation of lipaemic plasma from EDTA-blood in samples used in haematology can be performed by centrifugation and exchange of the cell-free supernatant with the same volume of isotonic NaCl solution.

4.4.5.2. Fluorine chlorinated hydrocarbon extraction

The extraction with fluorine chlorinated hydrocarbons, suggested many years ago, can no longer be recommended for reasons of environmental protection.

4.4.5.3. Polyethylene glycol

The plasma/serum sample is mixed 1 + 1 (v/v) with 8 % polyethylene glycol 6000, incubated for 30 min in a refrigerator at 4 °C and centrifuged afterwards for 10 min at 4 °C and approx. 1000 x g. The results determined in the clear supernatant are multiplied by the dilution factor 2 (148, 161).

4.4.5.4. α -Cyclodextrin

200 g α -cyclodextrin are dissolved in 1 L distilled water and kept in a refrigerator. Before use, α -cyclodextrin solution must be brought to ambient temperature. Thoroughly mix one part of α -cyclodextrin solution with two parts of serum, and centrifuge for 1 min at 10 000 g. The clear supernatant can be used for analysis. The dilution must be considered when calculating the concentration of the constituent in the original serum sample.

Experiments revealed that the results on 20 serum constituents are not affected by the precipitation of lipoproteins using α -cyclodextrin (169).

4.4.5.5. Magnetic beads

With the exception of sodium, calcium, magnesium, chloride and creatinine, various clinical chemistry constituents can be determined using magnetic beads, with dextran sulfate (50 kD) coated in a concentration of 5 g/L and 250 mmol/L MgCl₂ for delipidation. Add 100 μ L reagent to 500 μ L serum, and mix briefly on the Vortex mixer. Leave the tube upright in a rack for a few minutes, containing a magnet at the bottom. It is absolutely necessary to centrifuge the sample briefly, because some magnetic beads may still remain in the supernatant and bind to the cuvette of the analytical system. Multiply the results using a dilution factor 1.2.

4.4.5.6. Other methods for delipidation

Four different procedures for the extraction of lipids from serum samples were examined (3), including Freon 113[®], dextrane sulfate 500 S, Aerosil 300 and a butanol/di-isopropylether mixture. It was found that the delipidation methods may substantially alter the concentrations of certain analytes.

4.4.5.7. Optical clearing systems

Commercial test kits may contain detergents such as triton X-100, cholic and desoxycholic acid, lipase or cholesterol esterase to remove turbidity in plasma or serum samples. The assigned concentrations of these substances are method dependent and should not be changed by the user.

4.4.6 Recommendation

A visible turbidity of a sample must be documented and reported with the results. Transparent sample containers must be used to detect turbidity. The methods used for the measurement of certain analytes that are affected by lipaemia must be listed, the methods for delipidation and the criteria for their application must be documented in the quality manual.

The method of choice for removal of turbidity from serum and plasma is a 10 min centrifugation in a micro-centrifuge with 10 000 g.

When chemicals are added (e.g. polyethylene glycol, α -cyclodextrin), the laboratory must prove that assigned method for measurement is not disturbed by the agent.

Samples submitted for the determination of lipids and other analytes may be delipidated only after measurement of the lipids. This applies also to lipid soluble drugs.

4.4.7 Test of interference by lipaemia

Various problems should be considered to examine the influence of lipaemia on analytical methods. Unfortunately, there is no uniform human lipid standard available. Patient samples with high lipid concentrations should not be frozen.

A 10 or 20 % emulsion of vegetable fat emulsion as applied in parenteral nutrition (4, 21, 27, 59, 61, 112, 131, 155) is suitable to simulate lipaemia. Significant differences between the effects of "physiological" and the artificially produced lipaemia were observed, particularly in measurements of urea and potassium (27). Therefore, the effect of lipaemia may not be examined using exclusively a model that contains artificial fat emulsions, because the observations may not be transferable to the biological condition.

4.5 The icteric sample

4.5.1 Appearance of different bilirubin species

Bilirubin occurs in plasma as a free molecule and covalently bound to albumin. In addition, water-soluble bilirubin conjugates exist as mono- and di-glucuronides (11). Studies on bilirubin interference mainly based on experiments in which free bilirubin or water-soluble di-taurobilirubin was added to serum (135). Under certain conditions the bilirubin molecules differ qualitatively and quantitatively in their effects of interference(61).

Conjugated bilirubin appears in urine, when present at increased concentrations in blood. In patients with proteinuria, bilirubin bound to albumin can also appear in urine.

After intra-cerebral bleedings non-conjugated (free) bilirubin causes xanthochromia of the cerebrospinal fluid. At increased permeability of the blood-brain barrier bilirubin bound to albumin can appear in the CSF.

4.5.2 Mechanisms of bilirubin interference

4.5.2.1. Spectral interference

Bilirubin has a high absorbance between 340 nm and 500 nm wavelengths. Therefore, the range of the linearity of a spectrophotometric procedure, using these wavelengths for the measurement of an analyte, can be a limiting factor because of the high background absorbance caused by bilirubin (48, 49). In coagulation analyzers using turbidimetric principle, a bilirubin concentration exceeding 25 $\mu\text{mol/L}$ causes clinically relevant changes of the measured values of antithrombin III. Interference of bilirubin at higher concentrations will also be significant in certain coagulation tests (156).

The reduction of absorption as a result of oxidation bilirubin in alkaline solution is the main cause for bilirubin interference in modifications of the Jaffé method without deproteinisation (48).

In a strongly acid solution the absorption of conjugated bilirubin shifts to the UV wavelengths. Therefore bilirubin interferes in the determination of phosphate using the phosphomolybdate method through its reducing effect (37, 61).

4.5.2.2. Chemical interference

Bilirubin interferes in oxidase/peroxidase based test systems. Proportionally to its concentration bilirubin reacts with H_2O_2 formed in the test system which causes systematically lower results in enzymatic procedures that are used for the measurement of glucose, cholesterol, triglycerides, urate and creatinine (61, 179). Bilirubin competitively interferes with dyes binding to albumin (115). However, di-taurobilirubin does not interfere in the procedure of dye binding to albumin (61).

4.5.3 Detection and documentation of increased bilirubin concentrations in clinical samples

The visual inspection of plasma or serum samples for the detection of hyperbilirubinaemia is often not sensitive enough. This is particularly true when samples are simultaneously stained by other pigments (e.g. haemoglobin and its derivatives). Moreover, adhesive labels on primary containers can impair visual inspection.

Hyperbilirubinaemia is directly detected in diluted samples that are measured at 450 and 575 nm (177). (The direct procedure of bilirubin measurement is only applied for the determination of hyperbilirubinaemia in newborns.) With the nutritional supply of carotenes or carotinoids, bilirubin concentration by direct measurement is overestimated (53). The common clinical chemical methods are applied to quantitatively measure the interference caused by bilirubin. It is advisable to separate and measure the different bilirubin fractions to assess the mechanism of interference (11).

4.5.4 Prevention of bilirubin interference

4.5.4.1. Method selection

The high prevalence of hyperbilirubinaemia in patients from intensive care, gastroenterological, surgical or paediatric departments makes it pertinent to select analytical methods that are less susceptible towards bilirubin interference.

Blanking procedures are useful to eliminate spectral bilirubin interferences, (48, 61). Parallel sample blank values give better results than methods in which reagents are added successively into a cuvette (61). Blanking procedures are often part of the analytical procedure, e.g. in the kinetic method for creatinine determination according to the Jaffé principle, when autoanalyzers are used (165).

The chemical interference of bilirubin in an analytical reaction is not eliminated by blanking procedures. $K_4 [Fe(CN)_6]$ effectively eliminates bilirubin interference in H_2O_2 -forming enzymatic methods based on the Trinder reaction (4). Moreover, optimal concentrations of components of the Trinder reaction can reduce the interference by bilirubin. A mixture of non-ionic tensides may reduce bilirubin interference like in the spectrophotometric determination of inorganic phosphate using phosphomolybdate (58).

4.5.4.2. Actions recommended to use in procedures sensitive to bilirubin

When procedures susceptible to bilirubin interference are used, the laboratory must know the limit of bilirubin concentrations where interference-free measurements are possible (application limit). The limit depends on the maintenance status of the analytical system and other variables. Unfortunately, manufacturers' data are not always available. For the determination of the application limit, 2 mL of 20 mg free bilirubin, dissolved in 0.1 mol/L NaOH, are mixed with 20 mg di-taurobilirubin, dissolved in 2 mL distilled water, in the dark. Five mL of non-icteric pool serum are added to 0.1 mL of the master solution to prepare a final bilirubin concentration of approximately 340 $\mu\text{mol/L}$ (20 mg/dL). Serial dilutions are prepared by mixing a non-icteric pool serum with the master solution at different proportions. The test solution must be used on the same day (135).

Suitable alternative procedures must be applied for samples that have bilirubin concentrations beyond the application limit. The procedures may require a pre-treatment of samples to remove bilirubin. For the determination of serum creatinine using a bilirubin susceptible enzymatic method the sample is pre-incubated with 4.4 kU/L bilirubin oxidase for 30 seconds (7). However, the low stability of bilirubin oxidase limits the practical application of this procedure. Ultrafiltration of serum was also used for the

elimination of bilirubin interference in creatinine assays (51). As bilirubin binds to proteins, serum is centrifuged in a centrifugable ultrafilter (cut off \approx 20 kD) for 15 min at 2000 *g* to remove bilirubin and obtain a completely protein-free ultrafiltrate. The volume depletion effect of proteins results in an approximately 4 % higher value for creatinine in the ultrafiltrate (51). The distribution of ionised low-molecular weight analytes on the diaphragm may be pH dependent which has an effect on the measurement results (49).

If procedures for the elimination of bilirubin are not applicable, alternative analytical principles should be applied. Immunological procedures for the measurement of serum albumin can be used to replace dye binding methods that are susceptible to bilirubin interference.

5 Samples and Stability of Analytes

Key for tables

- ⊕ Recommended sample
 - + Can be used without changes of result
 - (+) Can be used with limitations (see comments, in case of citrated plasma this indicates the need to consider dilution by citrate (74)).
 - Not recommended
- Decreased (\searrow) or increased (\nearrow) values may be measured in comparison to recommended samples.
- Blank field means no data were found in literature.
- Greek letters refer to the information provided by diagnostic companies, numbers in brackets to the references.

Information provided by Diagnostic Companies

α : ORTHO-Clinical Diagnostics; Vitros Systems

β : Abbott; Axsym, Architect

γ : Roche Diagnostics; Hitachi, Elecsys, Modular

$\gamma\gamma$: Roche Diagnostics; Cobas[®]INTEGRA

δ : Beckman-Coulter; Synchron LX/CX, Immage/Array, Access

ε : Dade Behring; Dimension[®], BN Systems, Stratus CS

κ : DPC Immulite

λ : Bio-Rad

μ : Bayer; ADVIA Centaur/ACS 180

Stability and half-life times

min = minute(s)

h = hour(s)

d = day(s)

w = week(s)

m = month(s)

y = year(s)

| Samples | | | | | | | | Stability | | | | | | | |
|--|-------|-------------------|------------------------|----------------|-------------|------|---------|----------------------|--|---------------------------|---------|---------|------------|---|------------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Amylase - pancreatic | + | + | +γ, γγ | (+) | | | | 9 - 18 h | 4 d ↘ | 1 y | 7 d | 7 d | | * Possible decrease of the activity by Mg and Ca binding at > 25 °C | 76, 121, 186, 202, 216 |
| - total | + | + | +γ, - γγ, δ, ↘↘* | (+)* | | | | 9 - 18 h | 4 d ↘ | 1 y | 7 d | 7 d | | | |
| Amyloid A (SAA) | + | + | | | | | | | | 3 m at 25 °C | 8 d ε | 3 d ε | | | |
| Androstendione | + | | | | | | | | 1 d ↘ | 1 y | 4 d | 1 d | | | 99 |
| Angiotensin converting enzyme (ACE) | + | | - | - | | | | | | 1 y | 7 d | 1d | | | |
| Anticonvulsive drugs see phenobarbital, valproic acid, phenytoine | + | | | | | | | | | | | | | | |
| Antimitochondrial antibodies (AMA) | + | | | | | | | | | 1 m | 7 d | 1d | | | |
| Antineutrophil cytoplasmic antibodies (ANCA) | + | | | | | | | | | 1 m | 7 d | 1d | | | |
| Antinuclear antibodies (ANA) | + | | | | | | | | | 1 m | 7 d | 1d | | | |
| Antiphospholipid antibodies | + | | | | | | | | | 1 m | 2 – 3 d | 1 d | | | |
| Antistaphylolysine | + | + | + | | | | | | | 6 m | 2 d | 2 d | | | |
| Antistreptodornase B | + | | | | | | | | | 3 m | 8 d | | | | |
| Antistreptokinase | + | | | | | | | | | | | | | | |
| Antistreptolysine | + | +β, γ, δ, -γγ | +β, γ, δ, -γγ | | | | | | | 6 m | 8 d | 2 d | | | |

| Samples | | | | | | | | Stability | | | | | | | |
|---|------------|-----------------------|---------------------------------|--|-------------|----------|----------|----------------------|--|---------------------------|------------|---------|------------|--|--------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Antithrombin III - functional - immunochemical | - | - | - + δ , ϵ | \oplus (+) δ , ϵ | | | + | 30 h | 8 h 2 d** | 1 m 1 y | 2 w 8 d | 2 d | | *Test by Pharmacia-Upjohn **After centrifugation | 75, 148, 192 |
| α_1 - Antitrypsin | + | + γ | + γ , - γ | (+) γ | | | | | 11 d 7 w (2- 6 °C) | 3 m | 5 m | 3 m | | EDTA and citrate ∇ | 186, 187, 191, 216 |
| APC resistance - functional screening test - genotyping factor V Leiden | - | - | - | \oplus | | \oplus | \oplus | | 30 min | 6 m (-70 °C) | 3 h | 3h | | Centrifuge within 30 min | |
| Apolipoproteins AI, B | + ∇ | + γ , δ | \oplus γ , δ | (+) | | | | | | 3 m | 8 d | 1 d | | | 29, 43 |
| Apolipoprotein E | + | | + | | | | | | 1 d | 3 m | 8 d | | | | 162 |
| ApoE-genotyping | | | | | \oplus | | | | 1 w (4 -8 °C) | 3 m | 1 w | | | Stability of ApoE ₂ > ApoE ₄ > ApoE ₃ | 162, 170 |
| Aspartate aminotransferase (ASAT, AST, GOT) | + ∇ | \oplus | +, - α ∇ | (+) | | | | 17 h | 7 d ∇ | 3 m | 7 d | 4 d | | | 76, 106, 186, 216 |
| Aspergillus - antigene detection - antibody | + + | | | | | | | | | | | | | | |
| Atrial natriuretic peptide (ANP) - prohormone (proANP) | | | +* + | | | | | | Unstable 6 h | | | | *Aprotinin | Centrifuge at 4 °C | 134, 138, 195 |
| Barbiturates (see also phenobarbital) | + | + | | | | | | 50 - 120 h | 2 d | 6 m | 6 m | 6 m | | | 26, 45, 196 |
| Bartonella spp. antibodies | + | | | | | | | | | | | | | | |
| Batroxobin time | - | - | - | \oplus | | | | | | 1 m | 4 h | 8 h | | Avoid heparinate contamination ∇ | 75, 186, 192 |

| Samples | | | | | | | | Stability | | | | | | | |
|--|--------|-------------------|--------------|----------------|-------------|------|---------|----------------------|--|---------------------------|------------|------------|--|---|-------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Benzodiazepine (see also diazepam, flunitrazepam) | + | + | | | | | | 25 - 50h | <1 d* | | 5m∇ | 5m∇ | | | 45, 102, 117, 196 |
| Bicarbonate | + | + | | | ⊕ | | | min | Unstable ∇ (30 min – 2 h at +4°C) | 2 w | 7 d | 1 d * | Keep tube closed | *1 h after opening the tube, see also blood gases | 22, 106, 216 |
| Bilirubin - conjugated - total (also in newborns) | + + | + + | + + | (+) (+) | | | | h 17 d | Unstable ∇ | 6 m 6 m | 7 m 7 d | 2 d 1 d | | Darkness required, when stored > 8 h | 76, 202, 216 |
| Blood cell surface markers (immunocytometry) | | | | | + | + | | | CD4 1d in heparinized blood | | | | | Special stabiliser recommended (Cyfix II) (157) | 157 |
| Blood gases (CO ₂ , O ₂ , pH) | | | | | ⊕ | | | min | < 15 min ∇ pO ₂ < 30 min pH, pCO ₂ < 60 min on ice | | 2 h * | | *In heparinized blood and closed tubes | Use closed gas tight tubes or capillaries | 15, 22 |
| Bordetella pertussis antibodies | + | | | | | | | | | | | | | | |
| Borrelia burgdorferi antibodies (Lyme disease) | + | | (+) | | | | | | | | | | | ELISA, Western blot | |
| Brain natriuretic peptide (BNP) - pro BNP | + | + | ⊕ ⊕ | | | | | | 4 – 5 h 2 d | 5 d | 5 d | 5 d | EDTA | | 44 |
| Brucella antibodies (Brucellose) | + | | | | | | | | | | | | | | |
| C ₁ -esterase inhibitor - functional assay - immunochemical | + + | | + | (+) ε + ε | | | | | | 1 m 1 y | 2 d 8 d | 6 h | | Stabilise plasma by freezing | 186 |
| CA 125 | + | + α, γ, μ | + α, γ, μ | (+) γ | | | | 5 – 10 d | 2 d ∇ | 3 m | 5 d | 3 d | | | 17, 163 |

| Samples | | | | | | | Stability | | | | | | | | |
|---|--------|-------------------|---------------|----------------|-------------|------|-----------|----------------------|--|---------------------------|------------|--------------|-----------------------------------|---|-----------------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| CA 15-3 | + | +α, γ, -μ | +α, β, γ, -μ | (+)γ | | | | 5 - 7 d | | 3 m | 7 d | | | | 163, 175 |
| CA 19-9 | + | +γ, μ | +γ, -μ | (+)γ | | | | 4 - 8 d | 7 d ↘ | 3 m | 30 d | 7 d | | | 163 |
| CA 72-4 | + | +γ | +γ | (+)γ | | | | 3 - 7 d | 3 d ↘ | 3 m | 30 d | 7 d | | | 163 |
| Cadmium | - | | ⊕ | - | | | | 10 - 35 y | 1 d in trace element tube | | | | Special tube | Released from red stopper | 164, 186, 216 |
| Calcitonin | + | + | + | | | | | min | 1h stabilized* | | | | *Aprotinin 400 KIU/mL | | 186 |
| Calcium - total - ionised (free) | + - | + (+) | ↘ ↘ | ↘ ↘ | + ⊕* | | | h min | 2 d ↘ 15 min ↗ 1 d* | 8 m | 3 w 2 h | 7 d 3 d** | *Use calcium-titrated heparin (9) | pH-dependent **Stable in gel tubes for 25 h & 72 h after centrifugation in closed tube (^91) | 78, 202, 216 19, 22, 91 |
| Campylobacter jejuni/fetus antibodies | + | | | | | | | | | | | | | | |
| Candida albicans - antibodies - antigen detection | + + | | | | | | | | | | | | | | |
| Carbamazepine | + | +α ↗, β, γ, δ | +β, γ | (+)α ↗, β, γ | | | | 10 - 25 h | 2 d | 1 m | 7 d | 5 d | | 10 % higher results in plasma (α) | 26, 45 |
| Carbohydrate deficient transferrin (CDT) | + | - | | | | | | 14 - 18 d | 3 d | y | 7 d | 7 d | | Method-dependent | 167 |
| Carcino-embryonic antigen (CEA) | + | +α, β, γ, μ | +α ↘, β, γ, μ | +γ | | | | 3 - 11 d | 7 d | 6 m | 7 d | 1 d | | EDTA reduces by 13 % ↘ α | 63, 133, 163, 175, 200, 216 |
| Cardiolipin antibody | + | | | | | | | | | 1 m | 2-3 d | 1d | | | |

| Samples | | | | | | | | Stability | | | | | | | |
|--|-------|-------------------|--------------|----------------|-------------|------|---------|----------------------|--|---------------------------|----------|---------|--------------------------------|---|----------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Catecholamines (epinephrine, norepinephrine) | - | ⊕ | (+) | - | | | | 3 - 5 min | 1 h if not stabilized | 1 m 6 m stabilised | 2 d | 1 d | Glutathione 1.2 g/L +EGTA (34) | EGTA plasma to be separated within 15 min and frozen at -20°C | |
| Chinidin | + | +β, γ | +β | (+) β | | | | 6 - 9 h | | 1 - 2 w | 1 d | | | | 45, 205 |
| Chlamydia antibodies (C. trachomatis, C. pneumoniae) | + | | (+) | | | | | | | | | | | After thawing leave for 3 - 4 d at room temperature before sampling DNA | 129 |
| Chloramphenicol | + | +β | + | (+) | | | | 2 - 5 h | | | | | | | 205 |
| Chloride | + | + | - | - | + | | | 1 h | 1 d ↘ | y | 7 d | 7 d | | | 22, 76 |
| Cholesterol | + | +, - α, γ, δ | +, - α, γ, δ | (+) | | | | | 7 d ↗ | 3 m | 7 d | 7 d | | | 10, 29, 43, 76 |
| Cholesterol, HDL | + | + | + δ, - α | - | | | | | 2 d ↗ | 3 m | 7 d | 2 d | | | 10, 29, 43 |
| Cholesterol, LDL | + | -, + γ | +, - γ | - | | | | | 1 d ↘ | 3 m | 7 d | 1 d | | | 10, 29, 43 |
| Cholinesterase, including dibucain number | + | + | +, - γ | | | | | 10 d | 7 d ↘ | 1 y | 1 y | 1 y | | | 63, 76, 84 |
| Circulating immuno-complexes (CIC) | + | | | | | | | | 4 h | 1 y | 8 h | 4 h | | | |
| Clostridium tetani toxine antibodies | + | | | | | | | | | | | | | | |
| Coagulation factors | | | | | | | | | | | | | | | 75, 189 |
| Factor II | - | - | - | ⊕ | | | | 41 - 72 h | | 1 m | | 6 h | | | 189 |
| Factor V | - | - | - | ⊕ | | | | 12 - 15 h | | 1 m | 2 d | 6 h | | Centrifuge at 4°C | 75, 136, 189 |
| Factor VII | - | - | - | ⊕ | | | | 2 - 5 h | | | Unstable | 6 h | | | 189 |
| Factor VIII | - | - | - | ⊕ | | | | 8 - 12 h | | 2 w | 4 h | 3 h | | | 75, 136, 189 |
| Factor VIII R: Ag | - | - | - | ⊕ | | | | 6 - 12 h | | 6 m | 7 d* | 7 d* | * Sodium azide | Five freezing-thawing cycles are possible | 193 |

| Samples | | | | | | | | Stability | | | | | | | |
|--------------------------------------|-------|-------------------|--------------|----------------|-------------|------|---------|----------------------|--|---------------------------|-------------|-------------|---|---|---------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Factor VIII R: Co | | | | ⊕ | | | | 6 h | | 6 m | 2 w* | 2 d | * Sodium acide | | 193 |
| Factor IX | - | - | - | ⊕ | | | | 18 - 30 h | | 1 m | | 6 h | | | 193 |
| Factor IX: Ag | - | - | - | ⊕ | | | | | | | | | | | |
| Factor X | - | - | - | ⊕ | | | | 20 - 42 h | | 1 m | | 6 h | | | 189 |
| Factor XI | - | - | - | ⊕ | | | | 3 - 4 d | | | Unstable | 6 h | | | 189 |
| Factor XII | - | - | - | ⊕ | | | | 50 - 70 h | | | Unstable | 6 h | | | 189 |
| Factor XIII | - | - | - | ⊕ | | | | 4 - 5 h | | 1 m | | 4 h | | | 189 |
| Cocaine | + | + | - | | | | | | < 10 min | 4 d | 30 d | <30 min | Fluoride, pH 5 | Cocaine is converted in vitro into its metabolites. | 79, 117, 172 |
| Benzoylcegonin Ecgoninmethylester | | | | | | | | | 5 d 10 d | | 5 d 10 d | 5 d 10 d | | | |
| Coeruloplasmin | + | + | +, - γγ | | | | | 4 d | | 1 y | 2 w | 8 d | | | 187, 191, 202 |
| Cold agglutinins | | | | | | | | | | | | | | Keep whole blood at 37°C (water bath) | |
| Complement C3 | + | +, -γγ | + γ, - γγ | (+) | | | | min | 1 d 2 d (C3c) (2 - 6°C) | 8 d | 8 d | 4 d | | Dependent on antibody, during storage C3c ↗ C3 ↘ | 191, 202, 216 |
| Complement C4 | + | + | + | (+) | | | | 12 h - 1 d | 1 d 2 d (2 - 6 °C) | 3m | 8 d | 2 d | | During storage C4 ↘, C4c ↗ | 202, 216 |
| Copper | + | + | - | - | | | | | 7 d | y | 2 w | 2 w | | Special tube to avoid contamination | 206, 216 |
| Corticotropin (ACTH) | | + | ⊕ | | | | | min | Unstable ↘ | 6 w | 3 h | 1 h | Aprotinin 400-2000 KIU/mL Mercaptoethanol 2μL/mL | Prevent binding to glass tubes by using plastic for storage | 44, 132, 186 |
| Corticotropin releasing hormone | +↘ | + | ⊕ | | | | | | | | 1 d | 11 - 18 h | | | 44 |
| Cortisol | + | + α, μ | + α, γ, μ | | | | | 1 h | 7 d | 3 m | 7 d | 7 d | | 11 % less in EDTA (α) | 34, 93, 216 |

| Samples | | | | | | | | Stability | | | | | | | |
|--|--------------------|-----------------------------|------------------------------|----------------|-------------|------|--------------|---|--|---------------------------|-----------|------------|---|--------------------|-----------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Corynebacterium diphtheriae toxine antibodies | + | | | | | | | | | | | | | | |
| Coxiella burnetii-antibodies (Q-Fieber) | + | | | | | | | | | | | | | | |
| Coxsackie virus antibodies | + | | | | | | | | | | | | | | |
| C peptide | + | + | ⊕ | | | | min | 6 h | 2 m | 5 d | 5 h | EDTA | | 44, 54, 132 | |
| C-reactive protein (CRP) | + | (+)** + α, γ, δ, ε | (+)* + α, γ, δ, ε | (+), + γ | | | 2 - 4 h | 3 w (2 - 6 °C) | 3 y | 2 m | 11 d | | *Method-dependent **Patient-dependent lower results | 191, 216 | |
| Creatinine | + | + | + | (+) | | | min | 2 - 3 d ↗ | 3 m | 7 d | 7 d | | | 76, 202, 216 | |
| Creatine kinase (CK) | + | + α, β, γ, δ | + β, γ, δ | (+) | | | 18 h | 7 d ↘ | 1 m | 1 m | 4 h | Darkness | CK-BB not stable | 76, 186, 202, 216 | |
| Creatine kinase MB - enzyme activity - molecular mass | + + | + , -α + β, γ, δ, - μ | + γ, δ + β, γ, δ , - μ | (+) δ (+) γ | | | 12 h 12 h | 7 d ↘ 7 d ↘ | 1 y 4 w | 7 d 7 d | 2 d 2d | SH reagent | | 124 | |
| C-terminal telopeptide of type I collagen (β-CrossLaps™) | + | + | + | | | | | 8 h | 3 m | 7 d | 1 h | pH 8.0 | Stability pH-dependent | 139 | |
| Cyclosporin A + G | - | - | - | - | | ⊕ | 10 - 27 h | 13 d | 3 m | 13 d | 21 d | EDTA | Store haemolysate | 6, 46, 88, 205 | |
| CYFRA 21-1 | + | + γ | + γ | (+) γ | | | min | 7 d | 6 m | 1 m | 7 d | | | 163 | |
| Cystatin C | + | + | + | | | | min | 7 d | 6 m | 1 m | 7 d | | More stable in EDTA | 47, 130 | |
| Cytokines - IFN-α, IFN-γ, -1α - IL-6 - IL-1β, sIL-2R , sIL, 6R, TNFα | - ↘ - ↘ | + ↗ + | ⊕ | | | | | 2 h (heparinized blood) 1 h (EDTA) | | 2 d 12 h ↘ | | | | 12, 32 | |

| Samples | | | | | | | | Stability | | | | | | | |
|---|-------|-------------------|-------------|----------------|-------------|------|---------|---|--|---------------------------|-------|---------|--|--|------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Cytomegalovirus - antigen detection (pp65) - DNA amplification - (CMV) antibodies | + | +β | +β | (+)β | | ⊕ | | | | | | | | | |
| D-Dimer | (+) | + | - | ⊕ | | | | 6 – 8 h | 8 - 24 h | 6 m | 4 d | 8 h | | | 16, 23, 189 |
| Dehydroepiandrosterone-sulfate (DHEA-S) | + | | | | | | | | 2 d ↘ | y | 2 w | 1 d | | | 34, 99 |
| Dengue virus antibodies | + | | | | | | | | | | | | | | |
| Diazepam | + | + | + | | | | | 25 – 50 h | | | 5 m | 5 m | | | 45, 117, 196 |
| Differential leucocyte count - Band neutrophils - Segmented neutrophils - Eosinophiles - Basophiles - Monocytes - Lymphocytes | - | - | - | - | | ⊕ | + | 2 h-3 y 6 – 7 h 1.5 – 3 y | 2 h-7 d* 2 – 12 h 3 – 12 h 12 h – 6 d 2 h – 2 d 2 – 12 h 3 h – 7 d | | | | Dry blood smear stable | K ₃ -or K ₂ -EDTA: Stability temperature- and instrument-dependent *Prepare blood smear within 3 h after sampling. Do not store EDTA blood in refrigerator | 73, 77, 159, 180 |
| Digitoxin | + | +α,β, γ, μ | +γ, μ | | | | | 6 – 8 d | | 6 m | 3 m | 2 w | | | 45, 216 |
| Digoxin | + | +α, β, γ, δ, μ | +β, γ, δ, μ | (+)β | | | | 1 – 2 d | | 6 m | 3 m | 2 w | | | 45, 216 |
| Disopyramide | + | + | + | (+) | | | | 4 – 9 h | | 5m | 2 w | | | | 45 |
| DNA und RNA analysis by amplification (PCR) | (+) | -* | | | -* | ⊕ | + | | DNA 1 w RNA 2 h | | | | RNA: 5 mmol/L Guanidinium-isothiocyanate | *Heparin inhibits Taq polymerase and restriction enzymes LiCl 1.8 mol/L eliminates this error. | 81, 82, 90, 201 |

| Samples | | | | | | | | Stability | | | | | | | |
|---|-------|-------------------|--------------|----------------|-------------|------|---------|----------------------|--|---------------------------|---------|---------|------------------|---|--------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Dopamine | | | + | | | | | 3 - 5 min | | 1 m | 2 d | 1 d | | | |
| Echinococcus spp. antibodies | + | | | | | | | | | | | | | | |
| ECHO virus antibodies | + | | | | | | | | | | | | | | |
| Elastase | | | | | | + | | | | | | | | | |
| Electrophoresis, proteins; see also lipid electrophoresis | ⊕ | (+) | | | | | | | | 3 w | 3 - 7 d | 1 d | | Fibrinogen to be considered when using heparinate plasma, may be eliminated by fibrin precipitation | 186, 190 |
| Entamoeba histolytica antibodies | + | | | | | | | | | | | | | | |
| Enterovirus antibodies | + | | | | | | | | | | | | | | |
| Epstein Barr virus - heterophilic antibodies (Paul Bunnel test) | + | | (+) | | | | | | | | | | | | |
| - anti-EBNA, -VCA, -EA); | + | | | | | | | | | | | | | IgG, IgM, IgA; ELISA, Western Blot | |
| Erythrocyte count | | | | | (+) | ⊕ | (+) | | 4 d 7 d (4 - 8 °C) | | 7 d* | 7 d* | | *EDTA-blood | 62, 77 |
| Erythrocyte sedimentation rate (ESR) | | | | | | | ⊕ | | 2 h | - | - | - | | 1 part citrate, 4 parts blood | 186 |
| Erythropoietin | + | + | + | | | | | 4 - 11 h | 6 - 24 h | 5 m | | 2 w | | Shipped frozen | 96, 186 |
| Estradiol (E ₂) | + | (+) γ, μ, +α | (+) γ, μ, +α | (+)γ | | | | | 1 d | 1 y | 3 d | 1 d | | | 34, 99, 216 |
| Estriol (E ₃) | (+) | + | | | | | | | | 1 y | 2 d | 1 d | | | 63 |
| Ethanol | + | ⊕ α, β, γ, δ | +β, γ, δ | (+)β, δ | | + | * | 2 - 6 h | 2 w ↗ ↘** | 6 m | 6 m | 2 w | EDTA/ Heparin | *10 g/L NaF recommended to stabilise **Evaporation, use closed tubes | 57, 117, 128 |

| Samples | | | | | | | | Stability | | | | | | | |
|---|----------|-------------------|-------------|----------------|-------------|------|---------|---|--|---------------------------|--------------|--------------|-------------------------------------|--|---------------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Fructosamine | + | + | + | | | | | 12 d | 12 h ↗ | 2 m | 2 w | 3 d | | | 183, 186 |
| Galactose 1-p-uridyl-transferase (Beutler test) | | | | | | + | | | | | | | | Erythrocytes | |
| Gastrin | + | ⊕* | + | (+) | | | | | 2 h | | 1 w* | 1 w* | *With aprotinin 2000 KIU/mL | Freeze serum as soon as possible | 45, 186, 218 |
| Gentamicin | + | +β, γ, δ | +β, γ, δ | (+)β | | | | 0.5 - 3 h (< 30 y of age) 1.5 - 15 h (> 30 y of age) | 4 h | 4 w | 4 w | 4 h | | | 45 |
| Glucagon | + | + | ⊕ | | | | | | Unstable | | 1.5 d | 30 h | Aprotinin 500-2000 KIU/mL | Stabilise | 132 |
| Glucose - capillary - venous | - - ↘ | - - ↘ | - - ↘ | - - ↘ | (+) | ⊕ | | min min | 10 min ↘ 10 min ↘ | 1 d* 1 d* | 7 d* 7 d* | 2 d* 2 d* | Fluoride, mono-iodoacetate, mannose | *Stabilised haemolysate and plasma | 39, 56, 63, 186, 202, 216 |
| Glutamate dehydrogenase | + | + | + | | | | | 18 h | | 4 w | 7 d | 7 d | | | 186, 216 |
| Glutamate oxaloacetic transaminase (GOT) see aspartate aminotransferase | | | | | | | | | | | | | | | |
| Glutamate pyruvate transaminase (GPT) see alanine aminotransferase | | | | | | | | | | | | | | | |
| γ-Glutamyl transferase (γ-GT) | + | + | (+) ↘, + α | (+) ↘, -γγ | | | | 3 - 4 d | 1 d ↘ | y | 7 d | 7 d | | | 76, 106, 186, 216 |
| Glycated albumin see fructosamine | | | | | | | | | | | | | | | 183 |
| Gold | + | | | | | | | | | | | | | | |
| Haematocrit | | | | | + | ⊕ | | | 1 d 4 d (4 - 8 °C) | | 4 d* | | *EDTA-blood, | K ₂ -superior to K ₃ -EDTA | 77 |
| Haemoglobin A _{1c} | | | | | | ⊕ | | 2 m | 3 d (EDTA blood) | 6 m* | 7 d* | 3 d* | | *Haemolysate | 63, 183 |

| Samples | | | | | | | | Stability | | | | | | | |
|--|-------|-------------------|-------------|----------------|-------------|------|---------|----------------------|--|---------------------------|-------|---------|----------------------------------|--|----------------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Hepatitis B virus DNA | + | | + | | | | | | | | | | | | |
| Hepatitis C virus - RNA amplification | + | | + | | | | | | | | | | | | 81 |
| Hepatitis D virus - RNA amplification | + | | + | | | | | | | | | | | | |
| Hepatitis E - RNA amplification | + | | + | | | | | | | | | | | | |
| Herpes simplex 1 or 2 virus antibodies | + | | | | | | | | | | | | | | |
| HHV 6 antibodies (human herpes virus 6) | + | | | | | | | | | | | | | | |
| HHV 6-, 7-, 8-DNA amplification | | | | | | ⊕ | | | | | | | | | |
| HI virus 1 - (provirus)DNA amplification | | | | | | ⊕ | | | | | | | | Several freezing/thawing cycles possible | 81, 83, 118 |
| HI virus 1 and 2 antibodies | + | + α, β | +β, δ | (+) α β, δ | | | | 5 – 14 d | 7 d↘ | | 5 d γ | 1 – 2 d | | | |
| HIV, viral load | | | | | + | + | + | 5 – 14 d | 7 d | | | | | | 197 |
| HLA-ABC typing | | | | | ⊕ | | | | | | | | | Ammonium heparinized blood | |
| HLA- B27 | | | | | | ⊕ | | | | | | 1 d | Citrate-phosphate dextrose (CPD) | Ammonium heparinized blood | |
| HLA DR typing | | | | | | ⊕ | | | | | | | | | |
| Homocysteine | + ↗ | + | + | (+) | | ⊕ λ | | | 1 h ↗ 6 h (2 – 6 °C) | 4 y | 4 w | 4 d | Sodium fluoride 4 g /L blood | Sample with EDTA/acidic citrate (0,5 mol/L). Store blood at 0 – 4 °C (207). haemolysed EDTA sample in detergent stable for 2 d (146). Serum>plasma | 5, 144, 146, 149, 207, 214 |

| Samples | | | | | | | Stability | | | | | | | | |
|---|----------|-------------------|---------------------|----------------|-------------|------|-----------|------------------------|--|---------------------------|-------|---------|------------|----------------------------------|------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| HTLV I - antibodies (T-cell leukemia) - (provirus) DNA amplification - RNA amplification | + | | + | | | ⊕ | | | | | | | | | 81 |
| Human chorion gonadotropin (βhCG) - free - total | + + | + α, β, γ | + β, γ | (+) α, γ | | | 12 - 36 h | 24 h (2 – 8 °C) | 4 w 1 y | 2 d 7 d | 1 d | | | | 94 |
| 3-Hydroxybutyrate | | | | | ⊕ | | | | | | | | | De-proteinisation of whole blood | |
| IgA | + | + γ, δ | + γ, δ | | | | 6 d | 8 d 1 m (2 – 6 °C) | 8 m | 8 m | 8 m | | | EDTA and citrate ↘ | 191, 202, 216 |
| IgD | ⊕ | | - ↘ | | | | 5 d | | 6 m | 7 d | 7 d | | | | |
| IgE antigen-specific IgE | ⊕ + | + γ, δ, ε, μ | - ↘ + γ, δ, ε, μ | (+) γ | | | 2.5 d | | 6 m | 7 d | 7 d | | | | |
| IgG IgG subclasses | + + | + γ, δ | ↘, + γ | - | | | 3 w | 11 d 1 m (2 – 6 °C) | 8 m | 8 m | 4 m | | | | 191, 202, 216 |
| IgM | + | + γ, δ | + γ, δ, - ↘ γ | | | | 5 d | 17 d 1 m (2 – 6 °C) | 6 m | 4 m | 2 m | | | | 191, 202, 216 |
| Immunoglobulin light chains (κ, λ) | + | + γ | + γ | | | | | | 6 m | 1 m | 7 d | | | | |
| Influenza virus ABC antibodies | + | | | | | | | | | | | | | | |
| Insulin | (+) ↘ | + | + | | | | min | 15 min | 6 m | 6 d | 1 d | | | | 44, 54, 186, 216 |

| Samples | | | | | | | | Stability | | | | | | | |
|---|-------|-------------------|-------------|----------------|-------------|------|---------|------------------------------|--|---------------------------|------------|-------------|---|--|----------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Iron (Fe) | + | + | ↘ | ↘ | | | | 3 h | 2 h↗ | y | 3 w | 7 d | | | 63, 202, 206, 216 |
| JC polyoma virus - antibodies (progressive multifocal leukoencephalopathy, PML) - DNA-amplification (PML) | + | | | | | | | | | | | | | | |
| Lactate | - ↗ | - ↗ | - ↗ | - | (+) | | | min | <5 min, unstable ↗↗ | 1 m* | 3d 2 w* | 8 h 6 d* | Mannose/fluoride, monoiodoacetate, deproteinisation | Use glycolysis inhibitor tube, if not immediately deproteinised *Deproteinised in whole blood | 9, 63, 186, 202, 216 |
| Lactate dehydrogenase (LDH) | (+) ↗ | ⊕ | + | (+) | | | | 10 - 54 h LDH 5 < LDH 1,2 | 1 h↗ | 6 w | 4 d | 7 d | | LDH platelet-dependent (42, 82, 137) | 76, 126, 202, 216 |
| Lead (Pb) | - | - | + | - | (+) | | | | | | | 7 d | | Special tube | 164 |
| Legionella antibodies | + | | | | | | | | | | | | | | |
| Leishmania spp. antibodies (visceral leishmaniosis) | + | | | | | | | | | | | | | | |
| Leptin | + | + | + | | | | | | | 2 y | 2 m | 3 - 6 d | | Five freeze/thaw cycles possible | 44, 203 |
| Leptospira spp. antibodies (Leptospirosis) | + | | | | | | | | | | | | | | |
| Leucocyte count | | | | | + | ⊕ | + | 6 - 7 h | 7 d | | 7 d | | | See also differential count | 41, 62, 77, 143 |
| Lidocaine | + | +β, γ | +β | | | | | 1 - 3 h | | | 6 h | | | Separator gel | 100 |
| Lipase | + | + ↘ α | - ↘ | - | | | | 7-14 h | | 1 y | 3 w | 7 d | | EDTA binds calcium (activator), 15 % less activated in heparin (α) | 186, 187, 202 |

| Samples | | | | | | | Stability | | | | | | | | |
|---|-------|-------------------|--------------|----------------|-------------|----------|-----------|----------------------|--|---------------------------|-------|---------|------------|---|-----------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Lipoprotein(a) | + | +γ, ε | +γ | -γ | | | | | | 3 m | 2 w | 2 d | | | 119, 142, 169, 216 |
| Lipoprotein electrophoresis | ⊕ | - | - | - | | | | | | | 2-5d | | | Store at -20 ° C with 15 % sucrose | |
| Listeria monocytogenes - antibodies - DNA amplification | + | | | | | ⊕ | | | | | | | | | |
| Lithium | + | +*, α | -, + α | - | | | 8 – 24 h | 1 h ↘ | 6 m | 7 d | 1 d | | | *Do not use Li-heparin | 205 |
| Lupus anticoagulant | - | - | - | ⊕ | | | | | 6 m | | 4 h | | | Centrifuge platelet free | |
| Lutropin (LH) | + | + α, β, - μ | + α, β, μ | | | | | 7 d | 1 y | 5 d | 3 d | | | | 34, 44, 94, 216 |
| Lymphocytic choriomeningitis virus (LCM) - antibodies - RNA amplification | + | | | | | ⊕ | | | | | | | | | |
| Lymphocyte subtypes | | | | | | (+) | | | | | | | | Special stabiliser recommended (Cyfix II) (157) | 157 |
| Magnesium (Mg) | +↗ | + | - | - ↘ | ⊕ | | | | 1 d ↗* | 1 y | 7 d | 7 d | | *Separate blood cells before analysis (95) | 39, 76, 166, 206, 216 |
| Malaria -plasmodium antibodies - plasmodium spp. - trypanosoma gambiense | + | | | | | ⊕ (+) | | | | | | | | Microscopic examination of whole blood Blood film of capillary blood | |
| Measles virus - antibodies - RNA amplification | + | | | | | ⊕ | | | | | | | | | |
| Mercury (Hg) | | | | | + | | | | | | | | | Special tube | |

| Samples | | | | | | | | Stability | | | | | | | |
|--|-------|-------------------|-------------------|----------------|-------------|------|---------|----------------------|--|---------------------------|-------|--|---|---|-----------------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Methadone | + | + | | | | | | | | | | | | | |
| Methotrexate | + | | | | | | 2 – 4 h | | 6 m | 3 d | | | | Light ↘ | 45, 187 |
| Microfilarias | | | | | + | + | | | | | | | | Concentrated sample | |
| β ₂ -Microglobulin | + | +γ | +γ | (+) | | | | 1 d | 6 m | 3 d | 3d | | | | 187 |
| Morbili virus - antibodies - DNA amplification | + | + | | | | | | | | | | | | | |
| Morphine, total* | + | + | | | | | | 21 d 6 m (4 °C) | 6 m | 6 m | 3 m | | | Light ↘ *After hydrolysis | 173 |
| Mumps virus antibodies | + | | | | | | | | | | | | | | |
| Mycobacterium spp. DNA amplification | | | | | | | | | | | | | | | |
| Mycoplasma pneumoniae antibodies | + | | | | | | | | | | | | | | |
| Myoglobin | + | +γ, δ, ε, μ | +γ, δ, ε, μ | (+) γ | | | 15 min | 1 h ↘ | 3 m | 1 w | 2 d | | | | 14, 33, 124, 186, 213 |
| Neisseria gonorrhoeae antibodies | + | | | | | | | | | | | | | | |
| Netilmycin | + | | | | | | 2 – 3 h | | | | | | | | |
| Neuron specific enolase (NSE) | + ↗ | ⊕ | | | | | <24 h | 2 h ↗ | 3 m | 3 d | 2 d | Heparin | | Increased in thrombocytosis Serum>plasma | 64, 186 |
| Nitrazepam | + | +β | +β | (+) β | | | | 1 w | 1 w | 1 w | | | | Light ↘ | 117, 196 |
| Opiates (see also morphine) | + | + | | | | | | | | | | | | | |
| Osmolality | + | + | | | | | | | 3 m | 1 d | 3 h | | | | 186, 216 |
| Osteocalcin | +* | +* | ⊕* | | | | min | 15 min | 8 w (-30 °C) | 2 d* | 8 h | *Aprotinin 2500 KIU/mL + EDTA (5mmol/L) | Three freezing/thawing cycles are possible. | 38, 111, 209 | |

| Samples | | | | | | | Stability | | | | | | | | |
|---|---------------------|---------------------------|-------------------------|----------------|-------------|------|-----------|----------------------|--|---------------------------|-------|---------|------------|--|----------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Pancreatic elastase | + | | + | + | | | | | | 6 m | 2 w | | | | |
| Pancreatic polypeptide | + | + | + | | | | | | | | 6 d | 2 d | | | 44 |
| Paracetamol | + | +α, β | +α, β | (+)β | | | | 1 – 4 h | | 45 d | 2 w | | | | 45, 205 |
| Parathyrin (PTH) | + κ ₂ | +γ, κ | ⊕ | (+)γ | | | | min | 6 h (2 – 3 d in EDTA blood) | 4 m | 1 d | 6 h | EDTA | 15 % lower concentrations in serum compared to EDTA plasma | 158 |
| Partial thromboplastin time (aPTT) | - | - | - | ⊕ | | | | | 8 – 12 h | 1 m | 2-8 h | 2-8 h | | Stability reduced in plasma of patients heparinized | 75, 101, 136, 189 |
| Parvovirus B 19 - antibodies (erythema infectiosum) - DNA amplification | + | | | | | | | | | | | | | | |
| Phencyclidine | + | | | | | | | | | | | | | | |
| Phenobarbital | + | +β, γ, γ ₂ , δ | +β, γ, δ | (+)β, γ, δ | | | | 2 – 6 d | 2 d | 6 m | 6 m | 6 m | | | 26, 45 |
| Phenytoin | + | +α, β, γ, δ | +β, γ, δ, -α | (+)β, γ, +α | | | | 1 – 8 d | 2 d | 5 m | 1 m | 2 d | | Unstable in SST tubes (10) Biological half-life shorter in children | 26, 45 |
| Phosphate, inorganic | (+) ↗ | ⊕ | -α, γ ₂ , +μ | (+)μ, -α | | | | min | 1 h ↗↗ | 1 y | 4 d | 1 d | | Platelet-dependent in serum (123) | 76, 202, 216 |
| Polio virus 1, 2, 3 antibodies | + | | | | | | | | | | | | | Neutralisation test | |
| Potassium (K) | (+) ↗ | ⊕ | - | - | + | | | min | 1 h ↗↗ | 1 y | 6 w | 6 w | | Platelet-dependent in serum > plasma (123, 202), haemolysis ↗ | 39, 70, 76, 202, 216 |
| Pre-albumin | + | +γ | +γ | | | | | | | 1 y | 6 m | 3 d | | | |

| Samples | | | | | | | Stability | | | | | | | | |
|---|-------|-------------------|------------------|----------------|-------------|------|-----------|----------------------|--|---------------------------|------------|------------|------------|---|--|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Primidone | + | + | + | (+) | | | | 6 - 8 h | | 5 m | 4 w | | | | 45 |
| Procainamide and N-acetyl-procainamide | + | +β, γ | +β, γ | (+)β | | | | 3 - 5 h 6 - 10 h | | 6 m | 2 w | | | | 45, 187 |
| Pro-calcitonin | + | +δ | + | (+) | | | | | 1 - 2 d | | 1 d | 4 h | | | 127 |
| Progesterone | + | +β, - α, μ | +β, μ, - α | | | | | | 7 d | 1 y | 7 d | 1 d | | | 34, 63, 216 |
| Prolactin | + | +β, δ, μ | +β, μ | - | | | | | 2 d | 1 y | 6 d | 5 d | | | 34, 44, 216 |
| Propaphenone | + | + | | | | | | | | | | | | | |
| Propoxyphene | + | + | | | | | | | | | | | | | |
| Prostata specific antigen (PSA) | | | | | | | | | | | | | | Three freezing thawing cycles possible | 25, 89, 114, 140, 141, 151, 163, 168, 212 |
| - free | + | +γ | +γ | | | | | 2 h - 7 d | 2 h | 1 m↗ | 1 d | | | | |
| - total | + | +γ, μ, -α | +γ, μ, -κ | (+)γ | | | | 4 - 7 d | 1 d | 3 m↘ - 2 y | 30 d | 7 d | | | |
| Protein, total | + ↘ | ⊕ | +γ, γγ, δ | (+) | | | | Complex | 1 d | 1 y | 4 w | 6 d | | Plasma results higher due to fibrinogen (Biuret method) | 186, 216 |
| Protein C | - | - | - | ⊕ | | | | 6 - 8 h | 1 d | 3 m | 7 d | 7 d | | Avoid freezing/thawing cycles | 75, 122 |
| Protein S | - | - | - | ⊕ | | | | 24 - 58 h | | 4 h | 4 h | 4 h | | Separate cell-free plasma directly after centrifugation | 16, 75, 189 |
| Protein S100 | + | | | | | | | | | | | | | | |
| Prothrombin time (thromboplastin time, Quick) | - | - | - | ⊕ | | | | | 4 h - 1 d* | 1 m | 8 h - 1 d* | 4 h - 1 d* | | Reagent-dependent | 2, 75, 147, 189, 192 |
| Pyruvate | - ↘ | - ↘ | - | - | +* | | | | < 1 min | | | | | *Only stable in deproteinised blood | |

| Samples | | | | | | | | Stability | | | | | | | |
|--|-------|-------------------|---------------------|----------------|-------------|------|---------|----------------------|--|---------------------------|-------|---------|------------|--|------------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Thyroid antibodies Thyroid peroxidase antibodies (anti-TPO) Thyroglobulin antibodies (anti-TG) | + | + | | | | | | | | 2 d | | | | | |
| Thyroxine (T ₄) | ⊕ | +β, γ, γγ, -α, μ | +α, β, γ, γγ, -α, μ | (+)γ | | | | 6 m | 7 d | 1 m | 7 d | 5 d | | | 34, 202, 216 |
| Thyroxine, free (fT ₄) | + | +β, γ, μ | +γ, μ | (+)γ | | | | | | 3 m | 8 d | 2 d | | | 216 |
| Thyroxine binding globulin (TBG) | + | + | | | | | | | 7 d | 1 m | 5 d | 5 d | | | 39, 187, 216 |
| Tick borne encephalitis virus antibodies | + | | (+) | | | | | | | | | | | | |
| Tobramycin | + | +β, γ, δ | +δ | (+)β | | | | 0.5 - 3 h | | 1 m | 3 d | < 2 h | | Lower results obtained in heparinized plasma | 45, 154, 205 |
| Toxoplasma gondii antibodies (IgA, IgG, IgM) | + | +β | +β | +β | | | | | | | 8 d | 8 d | | | |
| Transferrin | + | +γ, γγ | + | | | | | 8.5 d | 11 d 3 w (2 - 6 °C) | 6 m | 8 m | 4 m | | | 191, 202, 216 |
| Treponema pallidum - antibodies - DNA amplification | + | | | | | | | | | | | | | TPHA, IFT, FTA abs., VDRL, immunoblot | |
| Tricyclic antidepressants | + | +β | +β | (+)β | | | | | | | | | | | 31 |
| Triglycerides | + | + | +, -α | (+) | | | | 3 h - 3 d | 7 d ↗* | y | 7 d | 2 d | | *Decrease of triglycerides, increase of free glycerol, but only minor increase of total glycerol | 29, 76, 202, 216 |

| Samples | | | | | | | | Stability | | | | | | | |
|---|--------|--|---------------------|----------------|-------------|------|---------|----------------------|--|---------------------------|------------|------------|------------------|---|--------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Triiodothyronine (T ₃) - free (fT ₃) | ⊕ + | (+) ↗ β, γ, δ, μ + β, γ, μ | + μ + β, γ, μ | (+)γ | | | | 19 h | | 3 m 3 m | 8 d 2 w | 2 d 1 d | | Serum-plasma difference method-dependent | 208, 216 |
| Troponin I | + | +* δ - α, μ ↘ | + δ, - α, μ ↘ | | | + | | 2 d | | 4 w | 3 d | 3 h | | *Reduced concentration described in some patients (55, 181) | 74, 124 |
| Troponin T | + | +γ* | (+)γ | | | | | | 8 h | 3 m | 7 d | 1 d | | *Reduced concentration described in some patients (55, 181) | 124, 186 |
| Urea | + | + | + | | | | | min | 1 d ↗ | 1 y | 7 d | 7 d | | Do not use NH ₄ -heparin | 76, 216, 217 |
| Uric acid | + | + | + ↘ | (+) | | | | min | 7d ↗ | 6 m | 7 d | 3 d | | | 202, 216 |
| Valproate | + | + β, γ, δ | +β, γ, δ | (+) β | | | | 8 - 15 h | 2 d | 3 m | 7 d | 2d | | | 26, 45 |
| Vancomycin | + | + β | + | (+)β | | | | 4 - 10 h | | | | | | | 45, 205 |
| Varicella Zoster virus - antibodies - DNA amplification | + | | | | | | | | | | | | | | |
| Vasoactive intestinale polypeptide (VIP) | ↘ | ↘ | ⊕ | | | | | | | > 6 d | 6 d | 1 d | EDTA + aprotinin | | 44, 132 |
| Vasopressin (ADH) | ↘ | + | + | | | | | | | | 6 d | 1 d | EDTA | Freeze plasma | 44 |
| Vitamin A (retinol) | + | | | | | | | 11 h | | 2 y | 1 m | | | | 63, 186 |
| Vitamin B ₁ (thiamine) | | + | + | | | | | | | 1 y | | | | | 63, 85 |
| Vitamin B ₂ (riboflavin) | | + | + | | | | | | | 1 m | | | | | 63 |
| Vitamin B ₆ (pyridoxal phosphate) | | | ⊕ | | | | | | | d | h | 30min | EDTA, darkness | | 63, 85 |
| Vitamin B ₁₂ (cobalamin) | + | + | ⊕ | | | | | | | 8 w | 1 d | 15min | EDTA, darkness | | 63, 108 |

| Samples | | | | | | | | Stability | | | | | | | |
|---|-------|-------------------|-------------|----------------|-------------|------|---------|----------------------|--|---------------------------|----------|---------|------------------------------------|--|---------------|
| Analytes | Serum | Heparinate Plasma | EDTA Plasma | Citrate Plasma | Whole blood | | | Biological half-life | Stability in blood at room temperature | Stability in serum/plasma | | | Stabiliser | Remarks / Comments | Reference |
| | | | | | Hep | EDTA | Citrate | | | -20°C | 4-8°C | 20-25°C | | | |
| Vitamin C (ascorbic acid) | | + | | | | | | | 3 h (4 °C) | 3 w* | 3 h | | 60g/L metaphosphate, deproteinised | *Only with stabiliser | 63 |
| Vitamin D - 1.25-dihydroxy-cholecalciferol | + | | | | | | | | 3 d | | | 3 d | | | 63, 186, 216 |
| - 25-hydroxy-cholecalciferol | + | | | | | | | | 3 d | | | 3 d | | | |
| Vitamin E (tocopherol) | + | | ⊕ | | | | | | 8 h↘ | 1 y | 1 m | | EDTA | | 63, 186 |
| Vitamin K (transphylochinone) | | | + | | | | | | unstable | 3 m | unstable | | | UV light↘ | 63, 186 |
| Yersinia enterocolitica antibodies | + | | | | | | | | | | | | | | |
| Zinc (Zn) | - | + | - | - | | | | | 30 min↗ | 1 y | 2 w | 1 w | | Special tube, avoid contamination by stopper | 164, 202, 216 |

5.2 Urine

| Analyte | Stability in urine at | | | Stabilizer | Comments | Reference |
|---|---|------------|------------|--|-------------------------------------|--------------|
| | - 20 °C | 4 – 8 °C | 20 – 25 °C | | | |
| Albumin | 6 m | 1 m | 7 d | | | 80, 113, 184 |
| Aluminium | 1 y | 7 d | 3 d | | | 63, 164 |
| δ-Aminolevulinic acid | 1 m | 4 d | 1 d | pH 6 - 7, stabilized with 0.3 % NaHCO ₃ | Drugs ↗ Light ↘ | 184, 216 |
| Amphetamine | 1 y | | | | | 36 |
| α-Amylase | > 3 w | > 10 d | 2 d | | Saliva contaminates ↗↗ | 121 |
| Bence Jones protein (light chains κ, λ) | 6 m | 1 m | 7 d | | | 184 |
| Calcium | > 3 w | 4 d | 2 d | Acidify, pH < 2 | Crystallisation at cool temperature | 28 |
| Catecholamines Norepinephrine Epinephrine Dopamine | Unstabilised 20 d Unstabilised 1 y | 4 d 1 y | 4 d 3 w | Acidify, pH < 2 or EDTA (250 mg/L) and sodium metabisulfite (250 mg/L) | | 20 |
| Citrate | 4 w* | | 1 d* | *pH < 1,7 | Unstable in native urine | 78 |
| Cocaine metabolite Benzoylecgonine | 4 m | 3 w | | pH 5, ascorbic acid | | 36, 79, 117 |
| Codeine | 1 y | | | | | 36 |
| Copper | 1 y | 7 d | 3 d | | | 164 |
| Cortisol, free | 1 w | 1 w | 2 d | 10 g/L boric acid | | 28, 93, 206 |
| C-peptide | | 6 d | 19 h | | | 44 |
| Creatinine | 6 m | 6 d | 2 d | | | 28, 186 |

| Analyte | Stability in urine at | | | Stabilizer | Comments | Reference |
|--------------------------------------|-----------------------|-----------|----------------|-----------------------------------|---------------------------------------|--------------|
| | - 20 °C | 4 – 8 °C | 20 – 25 °C | | | |
| Cystine | > 1 y* | 3 m* | 7 d* | *Stabilised in HCl | | 78 |
| Ethanol | | 30d | | | | 57, 117 |
| Glucose | 2 d | 2 h↘ | 2 h ↘ | 10 mmol/L azide | Bacteria decrease stability. | 28, 186, 187 |
| 5-Hydroxyindole acetic acid | 2 d | 2 d | 2 h | Acidify | | 186, 216 |
| Hydroxyproline | 5 d | 5 d | 5 d | | | 186 |
| Immunoglobulin G (IgG) | Unstable | 1 m | 7 d | | | 80, 113, 184 |
| Iron | >1 y | 7 d | 3 d | | | 28 |
| Lysergic acid diethylamide (LSD) | 2 m | 1 m | 1 m | | | 36, 117 |
| α ₂ -Macroglobulin | | 7 d | 7 d | | | |
| Magnesium | 1 y | 3 d | 3 d | Acidify, pH < 2 | | 28, 78 |
| α ₁ -Microglobulin | 6 m | 1 m | 7 d | | | 80, 113, 184 |
| Morphine | 1 y | | | | | 36, 45, 119 |
| Myoglobin | >12d* | 12d* | 12d* | *pH >8.0 | Unstable at acid pH | 213 |
| N-Acetyl-β,D-glucosaminidase (β-NAG) | 1 m | 7 d | 1 d | | | 125 |
| N-telopeptides (NT _x) | 4 w | 5 d | | | | |
| Osmolality | > 3 m | 7 d | 3 h | | | 28 |
| Oxalate | > 4 m (at pH 1.5) | unstable↘ | < 1 h | pH <2, HCl 1 vol %, thymol 5 mL/L | Vitamin C ↗ | 78 |
| pH | | unstable↗ | | | Increase by NH ₄ formation | 28 |
| Phosphate, inorganic | | | 2 d at pH <5.0 | 1 vol % thymol, 5 mL/L | precipitates at alkaline pH | 28, 78 |

| Analyte | Stability in urine at | | | Stabilizer | Comments | Reference |
|---|------------------------|----------|--------------------|-----------------------------------|--------------------|--------------|
| | - 20 °C | 4 – 8 °C | 20 – 25 °C | | | |
| Porphobilinogen | 1 m* | 7 d* | 4 d* | *pH 6 – 7 by NaHCO ₃ | Acid pH↘ Light↘ | 186, 216 |
| Porphyrines Total porphyrine Uroporphyrine Heptacarboxyporphyrine Hexacarboxyporphyrine Pentacarboxyporphyrine Coproporphyrine Tricarboxyporphyrine Dicarboxyporphyrine | 1 m | 7 d | 4 d | 0.3 % NaHCO ₃ , pH 6-7 | Light ↘ | 63, 186 |
| | Stabilized at pH 6 - 7 | | | | | |
| Potassium | 1 y | 2 m | 45 d | | | 28 |
| Protein | 1 m | 7 d | 1 d | | | 28 |
| Pyridinium crosslinks (collagen crosslinks) | >1 y | | 6 w | | UV light ↘↘ | 204, 209 |
| Sediment | | 1 - 8 h | 1 – 2h | | | 28, 103, 105 |
| Acantocytes | | | 2 d | | | |
| Casts (hyaline and others) | | | 2 d | | | |
| Bacteria | | 24 h | 1 – 2 h↗*** | | | |
| Epithelial cells | | | 3 h | | | |
| Erythrocytes | | 1-4 h | 1 h, 24 h* | | | |
| Leukocytes | | 1-4 h | 24 h** <1 h *** | | | |
| Sodium | 1 y | 45 d | 45 d | | | 28 |

Osmolality >300 mosmol/kg

*>300 mosmol./kg

**pH <6,5

***pH >7,5

Do not freeze

| Analyte | Stability in urine at | | | Stabilizer | Comments | Reference |
|--|-----------------------|-----------------|----------------------------|------------|---|--------------|
| | - 20 °C | 4 – 8 °C | 20 – 25 °C | | | |
| Test-strip fields Erythrocytes Leukocytes Protein | | 1 - 3 h 1 d* | 4 – 8 h 1 d ↗ >2 h** | | * >300 mosmol./kg ** Unstable at pH >7.5 | 28, 103, 105 |
| Transferrin | 4 w | 1 w | 7 d | | | 113 |
| Urea | 4 w | 7 d | 2 d | pH < 7 | | 28 |
| Uric acid | Unstable | | 4 d | pH >8 | Precipitation at pH <7 | 28, 78 |
| Vanillyl mandelic acid (VMA) | >1 y | >7d | 7d at pH 3 - 5 | pH <5 | | 28, 186, 216 |

5.3 Cerebrospinal Fluid (CSF)

| Analyte | Stability in urine at | | | Stabilizer | Comments | Reference |
|----------------|-----------------------|----------|-------------|---|---|-----------|
| | - 20°C | 4-8°C | 20-25°C | | | |
| Albumin | >1 y | 2 m | 1 d | Up to 1h: Do not cool Up to 3 h: Transport on ice No additives No partial fixation Long term storage Immediately -70 °C in glass or polypropylene vessels tightly closed | Glucose lactate: Stability depends on cell content IgG: Freezing is not recommended Leukocytes, tumor cells: Store cells as dry smears | 97, 98 |
| Glucose | >1m | 3 d | 5 h ↘ | | | |
| IgA, IgG, IgM | unstable | 7 d | 1 d | | | |
| Lactate | m | 1 h | 30 min ↗ | | | |
| Leukocytes | | 3-5 h | 1-2 h | | | |
| Protein, total | > 1 y | 6 d | 1 d | | | |
| Tumor cells | | 1 – 12 h | | | | |

6 References

1. Adcock D, Kressin D, Martar RA. Effects of 3.2 % vs. 3.8 % citrate concentration on routine coagulation testing. *Am J Clin Pathol* 1997; 107: 105-10.
2. Adcock D, Kressin D, Marlar RA. The effect of time and temperature variables on routine coagulation tests. *Blood Coagul Fibrinolysis* 1998; 9: 463-70.
3. Agnese ST, Spierito FW, Hannon WH. Evaluation of four reagents for delipidation of serum. *Clin Biochem* 1983; 16: 98-100.
4. Altura BT, Shirey TL, Young CC, Dell'Orfano K, Hiti J, Welsh R, Yeh Q, Barbour RL, Altura B. Characterization of a new ion selective electrode for ionized magnesium in whole blood, plasma, serum, and aqueous samples. *Scand J Clin Lab Invest* 1994; Suppl 217: 21-36.
5. Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. *Clin Chem* 1995; 41: 361-6.
6. Annesley TM, Hunter BC, Fidler DR, Giacherio DA. Stability of tacrolimus (FK 506) and cyclosporin G in whole blood. *Therap Drug Monit* 1995; 17: 361-5.
7. Artiss JD, McEnroe RJ, Zak B. Bilirubin interference in a peroxidase-coupled procedure for creatinine eliminated by bilirubin oxidase. *Clin Chem* 1984; 30: 1389-92. Artiss JD, Zak B. Problems with measurements caused by high concentrations of serum lipids. *CRC Crit Rev Clin Lab Sci* 1987; 25: 19-41.
8. Astles R, Wikliams CP, Sedor F. Stability of plasma lactate in vitro in the presence of antiglycolytic agents. *Clin Chem* 1994; 40: 1327-30.
9. Aufenanger J, Zawta B. Pre-analytical aspects of lipoprotein measurement. *Clin Lab* 1999; 45: 535-46.
10. Balistreri WF, Shaw LM. Liver function. In: Tietz NW, ed. *Textbook of Clinical Chemistry*. Philadelphia: Saunders, 1986, 1373-433.
11. Banks RE. Measurement of cytokines in clinical samples using immunoassays: Problems and pitfalls. *Crit Rev Clin Lab Sci* 2000; 37: 131-82.
12. Bauer K. Determination of free haemoglobin in serum by automated assay using 4-aminophenazone and the Cobas Bio system. *Clin Chem Clin Biochem* 1981; 19: 971-6.
13. Baum H, Bookslegers P, Steinbeck G, Neumeier D. A rapid assay for the quantification of myoglobin: evaluation and diagnostic relevance in the diagnosis of acute myocardial infarction. *Eur J Clin Chem Clin Biochem* 1994; 32: 853-8.
14. Beaulieu M, Lapointe Y, Vinet B. Stability of pO₂, pCO₂ and pH in fresh blood samples stored in a plastic syringe with low heparin in relation to various blood-gas and hematological parameters. *Clin Biochem* 1999; 32: 101-7.
15. Becker B, Denzler B, Kolde HJ, Ramirez I, Rombach B, Strauß J. Fehlermöglichkeiten bei Hämostasetests, Teil 1: Präanalytik, Reagenzien. *MTA* 1994; 9: 794-800.
16. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. *Clin Chem* 1999; 45: 1695-707.
17. Blank DW, Kroll MH, Ruddel ME, Elin RJ. Hemoglobin interference from in vivo hemolysis. *Clin Chem* 1985; 31: 1566-9.

18. Boink ABTJ, Buckley BM, Christiansen TF, Covington AK, Maas AHJ, Müller-Plathe O, et al. IFCC-Recommendations on sampling, transport and storage for the determination of concentration of ionized calcium in whole blood, plasma and serum. *Eur J Clin Chem Clin Biochem* 1991; 29: 767-72.
19. Boomsma F, Alberts G, van Eijk L, Man in't Feld, Schalekamp MADH. Optimal collection and storage conditions for catecholamine measurement in human plasma and urine. *Clin Chem* 1993; 39: 2503-8.
20. Brady J, O'Leary N. Interference due to lipaemia in routine photometric analysis - survey of an underrated problem. *Ann Clin Biochem* 1994; 31: 281-8.
21. Burnett RW, Covington AK, Fogh-Andersen N, Külpmann WR, Maas AHJ, Müller-Plathe O, et al. Approved IFCC recommendations on whole blood sampling, transport, and storage for simultaneous determination of pH, blood gases, and electrolytes. *Eur J Clin Chem Clin Biochem* 1995; 33: 247-53.
22. Caliezi C, Reber G, Lämmle B, de Moerloose P, Wuillemin WA. Agreement of D-dimer results measured by a rapid ELISA (VIDAS) before and after storage during 24 h or transportation of the original whole blood samples. *Thromb Haemost* 2000; 83: 177-8.
23. Callas DD, Clark TL, Moreira PL, Lansden C, Gawryl MS, Kahn S, Bermes EW. In vitro effects of a novel haemoglobin-based oxygen carrier on routine chemistry, therapeutic drug, coagulation, hematology, and blood bank assays. *Clin Chem* 1997; 43: 1741-8.
24. Cartledge JJ, Thompson D, Verril H, Clarkson P, Eardley I. The stability of free and bound prostate-specific antigen. *Brit J Urol* 1999; 84: 810-4.
25. Chetty M. The stability of anticonvulsant drugs in whole blood. *Ther Drug Monit* 1994; 16: 491-4.
26. Cobbaert C, Tricarica A. Different effects of Intralipid™ and triacylglycerol rich lipoproteins on Kodak Ektachem serum cholesterol determination. *Eur J Clin Chem Clin Biochem* 1993; 31: 107-9.
27. Colombo JP (ed.). *Klinisch-chemische Urindiagnostik*. Rotkreuz: Labolife, 1994.
28. Cooper RG, Sampson EJ, Smith SJ. Preanalytical, including biological variation in lipid and apolipoprotein measurements. *Curr Opin Lipidol* 1992; 3: 365-71.
29. Dale JC, Pruet SK. Phlebotomy - a minimalist approach. *Mayo Clin Proc* 1993; 68: 249-55.
30. Dasgupta A, Yared MA, Wells A. Time-dependent absorption of therapeutic drugs by the gel of Greiner Vacuette blood collection tube. *Ther Drug Monit* 2000; 22: 427-31.
31. De Jongh R, Vranken J, Vundelinckx, Bosmans E, Maes M, Heylen R. The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor. *Cytokine* 1997; 9: 696-701.
32. Delanghe JR, Chapelle JP, Vanderschueren SC. Quantitative nephelometric assay for determining myoglobin evaluated. *Clin Chem* 1990; 36: 1675-8.
33. Diver MJ, Hughes JG, Hutton JL, West CR, Hipkin LJ. The long-term stability in whole blood of 14 commonly-requested hormone analytes. *Ann Clin Biochem* 1994; 31: 561-5.
34. Dörner K, Böhler H. *Labordiagnostische Strategien in der Pädiatrie*. Darmstadt: GIT, 1996.
35. Dugan S, Bogema S, Schwartz RW, Lappas NT. Stability of drugs of abuse in urine samples stored at -20°C. *J Anal Toxicol* 1994; 18: 391-6.
36. Duncanson GO, Worth HGJ. Pseudohypophosphataemia as a result of bilirubin interference. *Ann Clin Biochem* 1990; 27: 263-7.
37. Durham BH, Robinson J, Fraser WD. Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. *Ann Clin Biochem* 1995; 32: 422-3.

38. Einer G, Zawta B. Präanalytik-Fibel. Leipzig, Heidelberg: Barth, 1991, 2nd ed.
39. Engstadt CS, Guttenberg TJ, Osterut B. Modulation of blood cell activation by four commonly used anticoagulants. *Thromb Hemost* 1997; 77: 690-6.
40. Erwa W, Bauer FR, Etschwaiger R, Steiner V, Scott CS; Sedlmayr P. Analysis of aged samples with the Abott CD 400 hematology analyzer. *Eur J Lab Med* 1998; 6: 4-15.
41. European IVD Directive for in vitro diagnostics. *Amtsblatt der Europäischen Gemeinschaften* L331/1 vom 7.12.1998
42. Evans K, Mitcheson J, Laker MF. Effect of storage at 4°C and -20°C on lipid, lipoprotein, and apoprotein concentrations. *Clin Chem* 1995; 41: 392-6.
43. Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. *Clin Biochem* 2000; 34:107-12.
44. Evans WE, Oellerich M, Holt DW. Drug monitoring, Leitfaden für die klinische Praxis. Wiesbaden: Abbott Diagnostics Division, 1994, 2nd ed.
45. Faynor SM, Rosbinson R. Suitability of plastic collection tubes for cyclosporin measurements. *Clin Chem* 1998; 44: 2220-1.
46. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry of the Behring nephelometer systems (BNA, BNII). *Clin Chem* 1997; 43: 1016-22.
47. Fonseca-Wollheim F da. Ringstudie zur Bilirubininterferenz bei der Bestimmung von Serum-Kreatinin. *Laboratoriumsmedizin* 1988; 12: 317-20.
48. Fonseca-Wollheim F da. Ultrafiltrate analysis confirms the specificity of the selected method for plasma ammonia determination. *Eur J Clin Chem Clin Biochem* 1992; 30: 15-9
49. Fonseca-Wollheim F da. Deamidation of glutamine by increased plasma γ -glutamyltransferase is a source of rapid ammonia formation in blood and plasma specimens. *Clin Chem* 1990; 36: 1479-82.
50. Fonseca-Wollheim F da, Heinze KG, Lomsky K, Schreiner H. Serum ultrafiltration for the elimination of endogenous interfering substances in creatinine determination. *J Clin Chem Clin Biochem* 1988; 26: 523-5
51. Fuentes-Arderiu X, Fraser CG. Analytical goals for interference. *Ann Clin Biochem* 1991; 28: 393-5.
52. Garb S. Clinical guide to undesirable drug interactions and interferences. New York: Springer, 1971.
53. Gerbitz KD. Pankreatische B-Zellenpeptide: Kinetik und Konzentration von Proinsulin, Insulin und C-Peptid in Plasma und Urin. Probleme der Meßmethoden, klinische Aussage und Literaturübersicht. *J Clin Chem Clin Biochem* 1980; 18: 313-26.
54. Gerhardt W, Nordin G, Herbert AK, Burzell BL, Isaksson A, Gustavsson E, et al. Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. *Clin Chem* 2000; 46: 817-21.
55. Giampetro O, Navalesi R, Buzzigoli G, Boni C, Benzi L. Decrease in plasma glucose concentration during storage at -20°C. *Clin Chem* 1980; 25: 1710-2.
56. Gibitz HJ, Schütz H. Bestimmung von Ethanol im Blut. *Mitt XX der Senatskommission für klinisch-toxikologische Analytik*. Weinheim: VCH Verlagsgesellschaft, 1993.
57. Glick MR, Pieper J, Ryder KW. Interference-reduced methodologies for Boehringer Mannheim/Hitachi analyzers: Validation using recombinant haemoglobin „blood substitute“ product. *Clin Chem* 1998; 44, Suppl. A 140.

58. Glick MR, Ryder KW, Glick SJ. Interferographs. Evaluation. Indianapolis: 2nd ed. Sciences Inc. 1991.
59. Goosens W, van Duppen V, Verwilghen RL. K₂- or K₃-EDTA: the anticoagulant of choice in routine haematology? Clin Lab Haemat 1991; 13: 291-5.
60. Grafmeyer D, Bondon M, Manchon M, Levillain P. The influence of bilirubin, haemolysis and turbidity on 20 analytical tests performed on automatic analysers. Eur J Clin Chem Clin Biochem 1995; 33: 31-52
61. Grasselt M, Platen U, Zawta B. Erfahrungen mit Venenblut in der ambulanten hämatologischen Routinediagnostik. Dtsch Ges Wesen 1972; 27: 1844-7.
62. Greiling H, Gressner AM (eds.). Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart: Schattauer, 1995, 3rd ed.
63. Gross J, Ungethüm U, Moller R, Priem F, Heldt J, Ziebig R, et al. Preanalytical factors influencing the measurement of NSE levels in blood. J Lab Med 1995; 18: 286-9.
64. Guder WG. Haemolysis as an influence and interference factor in clinical chemistry. J Clin Chem Clin Biochem 1986; 24: 125-6.
65. Guder WG, da Fonseca-Wollheim F, Heil W, Müller-Plathe O, Töpfer G, Wisser H, et al. Stabilität der Meßgrößen in der Probenmatrix. Klin Chem Mitt 1995; 26: 205-24.
66. Guder WG, da Fonseca-Wollheim F, Heil W, Müller-Plathe O, Töpfer G, Wisser H, et al. Wahl des optimalen Probenvolumens. Klin Chem Mitt 1996; 27: 106-7.
67. Guder WG, Ehret W, da Fonseca-Wollheim F, Heil W, Müller-Plathe O, Töpfer G, et al. Serum, plasma or whole blood? Which anticoagulants to use? Lab Med 1998; 22: 297-312
68. Guder WG, da Fonseca-Wollheim F, Heil W, Schmitt Y, Töpfer G, Wisser H, et al. The haemolytic, icteric and lipemic sample. Recommendations regarding their recognition and prevention of clinically relevant interferences. J Lab Med 2000; 24: 357-64.
69. Guder WG, Narayanan S, Wisser H, Zawta B. Samples: From the Patient to the Laboratory. Darmstadt: GIT, 2001, 2nd ed.
70. Hagemann P. Qualität im Arztlabor. Optimierung der Präanalytik. Heidelberg: Springer, 1994.
71. Hallbach J, Hoffmann GE, Guder WG. Overestimation of albumin in heparinized plasma. Clin Chem 1991; 37: 566-8.
72. Hauswaldt C, Schröder U. Differentialblutbilder im EDTA-Blut. Fehlermöglichkeiten und Grenzen. Dt Med Wschr 1973; 98: 2391-7.
73. Heeschen C, Goldmann BU, Langenbrink L, Matschuk G, Hamm CW. Evaluation of a rapid whole blood ELISA for quantification of troponin I in patients with acute chest pain. Clin Chem 1999; 45: 1789-96.
74. Heil W, Grunewald R, Amend M, Heins M. Influence of time and temperature on coagulation analytes in stored plasma. Clin Chem Lab Med 1998; 36: 459-62.
75. Heins M, Heil W, Withold W. Storage of serum or whole blood samples? Effect of time and temperature on 22 serum analytes. Eur J Clin Chem Clin Biochem 1995; 33: 231-8.
76. Heins M, Schossow B, Greiner L, Heil W. Influence of storage time and temperature on haematological measurands using a Sysmex NE 8000 analyser. J Lab Med 2000; 24: 236-42.
77. Hesse A, Claßen A, Röhle G. Labordiagnostik bei Urolithiasis. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1989.
78. Hippenstiehl MJ, Gerson B. Optimization of storage conditions for cocaine and benzoylecgonine in urine: a review. J Anal Toxicol 1994; 18: 104-9.

79. Hofmann W, Guder WG. Präanalytische und analytische Faktoren bei der Bestimmung von IgG, Albumin, α_1 -Mikroglobulin und Retinol-bindendem Protein im Urin mit dem Behring Nephelometer System (BNS). *J Lab Med* 1989; 13: 470-8.
80. Holodniy, M. Effects of collection, processing, and storage on RNA detection and quantification. In: Kochanowski B, Reischl U (eds.) *Quantitative PCR-Protocols*. Totowa (USA): Humana Pr, 1999.
81. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves EW, Merigan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. *J Clin Microbiol* 1991; 29: 676-9.
82. Holodniy M, Rainer L, Herman S, Yen-Lieberman B. Stability of plasma immunodeficiency virus load in vacutainer PPT plasma preparation tubes during overnight shipment. *J Clin Microbiol* 2000; 38: 323-6.
83. Huizenga JR, van der Belt K, Gips CH. The effect of storage at different temperatures on cholinesterase activity in human serum. *J Clin Chem Clin Biochem* 1985; 23: 283-5.
84. Ishii H, Sarai K, Sanemori H, Kawasaki T. Analysis of thiamine and its phosphate esters by high-performance liquid chromatography. *Anal Biochem* 1979; 97: 191.
85. ISO/DIS 6710. Single-use containers for human venous blood specimen collection. Draft 2001.
86. ISO GUIDE 30. Terms and definitions used in connection with reference materials. 1992; 30, 2nd ed.
87. Johnston A, Cullen G, Holt DW. Quality assurance for cyclosporin assays in body fluids. *Ann Acad Med Singapore* 1991; 20: 3-8.
88. Jung K, Klinggraeff P von, Brux B, Sinha P, Schnor L, Loening SA. Preanalytical determinations of total and free prostate-specific antigen and their ratio: blood collection and storage conditions. *Clin Chem* 1998; 44: 685-8.
89. Jung R, Lübecke C, Wagener C, Neumaier M. Reversal of rt-PCR inhibition observed in heparinized clinical specimens. *Biotechniques* 1998; 23: 24-8.
90. Kallner A. Preanalytical procedures in the measurement of ionized calcium in serum and plasma. *Eur J Clin Chem Clin Biochem* 1996; 34: 53-8.
91. Kazmierczak SC, Catrou PG, Best AE, Sullivan SW, Briley KP. Multiple regression analysis of interference effects from a haemoglobin-based-oxygen carrier solution. *Clin Chem Lab Med* 1999; 37: 453-64.
92. Keiichi M, Suday A, Kawasaki J. Effect of urine pH, storage time and temperature on stability of catecholamines, cortisol, and creatinine. *Clin Chem* 1998; 44: 1759-62.
93. Keller H. *Klinisch-chemische Labordiagnostik für die Praxis*. Stuttgart: Thieme, 1991, 2. Aufl.
94. Keller RH, Lymans S. α -Fetoprotein: biological and clinical potential. In Rhodes BA (ed.). *Tumor Imaging*. New York: Masson Publ 1982: 41-52.
95. Kendall RG, Chapman C, Hartley AE, Norfolk DR. Storage and preparation of samples for erythropoietin radioimmunoassay. *Clin Lab Haematol* 1991; 13: 189-96.
96. Kleine TO, Baerlocher K, Niederer V, Keller H, Reuther F, Tritschler W, et al. Diagnostische Bedeutung der Lactatbestimmung im Liquor bei Meningitis. *Dt Med Wschr* 1979; 104: 553-7.
97. Kleine TO, Hackler R, Lehmitz R, Meyer-Riemecker H. Liquordiagnostik: klinisch-chemische Kenngrößen: Eine kritische Bilanz. *Klin Chem Mitt* 1994; 25: 199-214.
98. Kley HK, Rick W. Einfluß von Lagerung und Temperatur auf die Analyse von Steroiden in Plasma und Blut. *J Clin Chem Clin Biochem* 1984; 22: 371-8.
99. Koch TR, Platoff G. Suitability of collection tubes with separation gels for therapeutic drug monitoring. *Ther Drug Monit* 1990; 12: 277-80.

100. Köhler M, Dati F, Kolde HJ. Aktivierte partielle Thromboplastinzeit (aPTT)-Standortbestimmung - Standardisierung der Methode, Interpretation der Befunde und Grenzen der Anwendbarkeit. *J Lab Med* 1995; 19: 162-6.
101. Koenig I, Skopp G, Aderjan J, Koenig S. Stabilität von Benzodiazepinen in Blut und Plasma bei Licht- und Wärmeexposition. *Klin Paediatr* 1999; 211: 122, Abstr, Nr. V8.
102. Koivula T, Groenroos P, Gävert J, Icen A, Irjala K, Penttilä I, et al. Basic urinalysis and urine culture: Finnish recommendations from the Working Group on clean midstream specimens. *Scand J Clin Lab Invest* 1990; 50 (Suppl. 200): 26-33.
103. Korte W, Riesen WF. Comparability of serum and plasma concentrations of haemostasis. *Clin Chem Lab Med* 2001; 39: 627-30.
104. Kouri T, Fogazzi G, Gant V, Hallander H, Hofmann W, Guder WG. European urinalysis guidelines. *Scand J Clin Lab Invest*, 2000; 60 Suppl 231: 1-96.
105. Kreutzer HJH, Paanakker MPWM. Stability of routine chemistry parameters in lithium heparin gel tubes. *Proc 11th Eur Congr Clin Chem*, Tampere 1995, abstr. 357.
106. Külpmann WR. Determination of electrolytes in serum and serum water. *Wiener Klin Wschr* 1992; Suppl: 34-8.
107. Kuhl L, Tamm A. On the stability of vitamin B₁₂, folic acid and ferritin in serum. *Quality of Preanalytical Phase in Europe*, Leuven: Terumo 2001
108. Lammers M. Dilution of citrated plasma. *Eur J Clin Chem Clin Biochem* 1996; 34: 369.
109. Lammers M, Gressner AM. Immunonephelometric quantification of free haemoglobin. *J Clin Chem Clin Biochem* 1987; 25: 363-7.
110. Lang M, Seibel MJ, Zipf A, Ziegler R. Einfluß eines neuen Proteolysehemmers auf die Haltbarkeit von Osteocalcin im Serum. *Klin Lab* 1996; 42: 5-10.
111. Leary NO, Pembroke A, Duggan PF. Measuring albumin and calcium in serum in a dual test with the Hitachi 704. *Clin Chem* 1992; 38: 1342-5.
112. Ledue TB, Collins MF, Craig WY, Ritchie RF. Effect of storage time, temperature and preservative on IgG, transferrin, albumin and alpha-1-microglobulin levels in urine. *Clin Chem* 2000; 46, Suppl.: A 48 (abstract).
113. Leinonen J, Stenman UH. Reduced stability of prostate-specific antigen after long-term storage of serum at -20 °C. *Tumour Biol* 2000; 21: 46-53.
114. Leonard PJ, Persaud J, Motwani R. The estimation of plasma albumin by BCG dye binding on the Technicon SMA 12/60. *Clin Chim Acta* 1971; 35: 409.
115. Leppänen E, Gräsbeck R. The effect of the order of filling tubes after venipuncture on serum potassium, total protein, and aspartate and alanine aminotransferase. *Scand J Clin Lab Invest* 1986;46: 189-91.
116. Levine B, Smith ML. Stability of drugs of abuse in biological specimens. *Forensic Sci Rev* 1990; 2: 148-56.
117. Lew J, Reichelderfer P, Fowler M, Bremer J, Carrol R, Cassols S, et al. Determination of levels of human immunodeficiency virus Type 1 RNA in plasma: reassessment of parameters affecting assay outcome. *J Clin Microbiol* 1998; 38: 1471-9.
118. Lippi G, Giampaolo L, Giancresce G. Effect of anticoagulants on lipoprotein(a) measurements with four commercial assays. *Eur J Clin Chem Clin Biochem* 1996; 34: 251-5.
119. Lippi U, Schinella M, Nicoli M, Modena N, Lippi G. EDTA induced platelet aggregation can be avoided by a new anticoagulant also suitable for automated blood count. *Haematologia* 1990; 75: 38-41.

120. Lorentz K. Approved Recommendation on IFCC methods for the measurements of catalytic concentration of enzymes. Part 9. IFCC method for α -amylase (1,4- α -D-glucan 4-glucanohydrolase, EC 3.2.1.1). *Clin Chem Lab Med* 1998; 36: 185-203.
121. Luddington R, Peters J, Baker P, Baglin R. The effect of delayed analysis or freeze-thawing on the measurement of natural anticoagulants, resistance to activated protein C and markers of activation of the haemostatic system. *Thromb Res* 1997; 87: 577-81.
122. Lutomski DM, Bower RH. The effect of thrombocytosis on serum potassium and phosphorus concentration. *Am J Med Sci* 1994; 307: 255-8.
123. Mair J, Puschendorf B. Aktuelle Aspekte der Labordiagnostik des akuten Myokardinfarktes. *J Lab Med* 1995; 19: 304-18.
124. Matteucci E, Giampetro O. To store urinary enzymes: How and how long? *Kidney Int* 1994; Suppl 47: 58-9.
125. McKenzie D, Henderson A. Electrophoresis of lactate dehydrogenase isoenzymes. *Clin Chem* 1983; 29: 189-95.
126. Meisner M, Tschaikowsky K, Schnabel S, Schmidt BJ, Kataliuvic A, Schüttler J. Procalcitonin - influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. *Eur J Clin Chem Clin Biochem* 1997; 35: 597-601.
127. Meyer T, Monge PK, Sakshaug J. Storage of blood samples containing alcohol. *Acta Pharmacol Toxicol* 1979; 45: 282-6.
128. Morre SA, Van Valkengoed IGM, De Jong A, Boeke AJP, Van Eijk JTM, Meijer CJLM, et al. Mailed, home-obtained urine specimen: a reliable screening approach for detecting asymptomatic *Chlamydia trachomatis* infections. *J Clin Microbiol* 1999; 37: 976-80.
129. Mussap M, Ruzzante N, Varagnolo M, Plebani M. Quantitative automated particle-enhanced immunonephelometric assay for the routinary measurement of human cystatin C. *Clin Chem Lab Med* 1998; 36: 859-65.
130. Nanji AA, Poon R, Hineberg I. Lipaemic interference: Effects of lipaemic serum and Intralipid. *J Clin Pathol* 1998; 41: 1026-7.
131. Narayanan S. Protection of peptidic substrates by protease inhibitors. *Biochim Clin* 1987; 11: 954-6.
132. Narayanan S. Quality control in tumor marker analysis: preanalytical issues. *J Clin Ligand Assay* 1998; 21: 11-7.
133. Narayanan S. The preanalytical phase. An important component of laboratory medicine. *Am J Clin Pathol* 2000; 113: 429-52
134. National Committee for Clinical Laboratory Standards. Interference testing in clinical chemistry; Proposed Guideline. NCCLS publication EP7-P. Villanova: NCCLS, 1986.
135. NCCLS Document H21-A3. Collection, transport, and processing of blood specimens for coagulation testing and general performance of coagulation assays. Wayne, PA: 2000, 3rd ed.
136. Neumaier M, Braun A, Wagener C. Fundamentals of quality assessment of molecular amplification methods in clinical diagnostics. *Clin Chem* 1998; 44: 12-26.
137. Numata Y, Doki K, Furukawa Akikuoka S, Asada H, Fukonaga T, et al. Immunoradiometry assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma. *Clin Chem* 1998; 44: 1008-13.
138. Okabe R, Nakatsuka K, Imada M, Miki T, Naka H, Nasaki H, et al. Clinical evaluation of the Elecsys β -crosslabs serum assay, a new assay for degradation products of type I collagen C-telopeptides. *Clin Chem* 2001; 47: 1410-4.

139. Oremek GM, Seiffert UB. Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. *Clin Chem* 1996; 42: 691-5.
140. Ossendorf M, Fichtner J, Schroeder S, Thueroff JW, Prellwitz W. In vitro Stabilität des freien prostataspezifischen Antigens (PSA) in Serum- und Vollblutproben. *Anticancer Res* 1997; 17: 4199, No 6C, Abstr. No 58.
141. Panteghini M, Pagoni F. Pre-analytical, analytical and biological sources of variation of lipoprotein(a). *Eur J Clin Chem Clin Biochem* 1993; 31: 23-8.
142. Pararo C, Tagini E, Meda R, Scott CS, Novaro O. Improved stability of leucocytes in aged samples: investigation of an alternative anticoagulant strategy in hematology for use with the Abbott Cell-Dyn CD 3500 hematology analyzer. *Eur J Lab Med* 1998; 6: 16-23.
143. Pfund A, Wendland G, Geisen C, Hoepf HW. Reliability of homocysteine measurement. *Herz/Kreislauf* 1999; 33: 381-5.
144. Polack B, Mossuz P, Barro C, Pernod G. Pre-analytical phase in haemostasis. Proceedings of the First Symposium on the impact of the pre-analytical phase on the quality of laboratory results in haemostasis; 1996 Oct 14; Montpellier (France). Becton Dickinson 1996.
145. Probst R, Brandl R, Blümke M, Neumeier D. Stabilization of homocysteine concentration in whole blood. *Clin Chem* 1998; 44: 1567-9.
146. Rao LV, Okorodudu AO, Petersen JR, Elghetany MT. Stability of prothrombin time and activated partial prothrombin time tests under different storage conditions. *Clin Chim Acta* 2000; 300: 13-21.
147. Rasbold K, Rendell MS, Goljan E. Simple removal of lipids from serum. *Clin Chem* 1985; 31: 782.
148. Rasmussen K, Møller J, Lyngbak M, Holm Pedersen AM, Dybkaer L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. *Clin Chem* 1996; 42: 630-6.
149. Reiter W, Göhring P, Stieber P, Pahl H, Kempter B, Banauch D. The influence of blood taking, storage conditions and interfering factors on a new fibrin monomer test. *J Lab Med* 1996; 20: 112-6.
150. Richardson TD, Wojno KJ, Liang LW, Giacherio DA, England BG, Henricks WH, et al. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. *Urology* 1996; 48: 40-4
151. Richtlinie der Bundesärztekammer zur Qualitätssicherung quantitativer laboratoriumsmedizinischer Untersuchungen. *Dt Ärztebl* 2001; 98: B2356-67.
152. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, et al. Current databases on biological variation: pros, cons and progress. *Scand J Clin Lab Invest* 1999; 59: 491-500
153. Rodriguez-Mendizabal M, Lucena MI, Cabello MR, Blanco E, Lopez-Rodriguez B, Sanchez de la Cuesta F. Variations in blood levels of aminoglycosides related to in vitro anticoagulant usage. *Ther Drug Monit* 1998; 20: 88-91.
154. Roß RS, Eller T, Volbracht L, Paar D. Interferenzen durch Lipämie, Hämolyse und Hyperbilirubinämie am DAX 48-Analysator und ihre klinische Relevanz. *Lab Med* 1994; 18: 233-9.
155. Roß RS, Paar D. Analytisch und klinisch relevante Interferenzen in der Gerinnungsanalytik am Beispiel des MDA 180. *J Lab Med* 1998; 22: 90-4.
156. Ruf A, Patscheke H. Whole blood stabilization for the immunocytometric analysis of blood cells. In: *Samples from patients to laboratories. The impact of the preanalytical phase on the quality of*

- laboratory results. Proceedings of the of 3rd Symposium in Basel/Switzerland, Aug 15-16, 1997. Meylan: Becton Dickinson, 1997: 24.
157. Russell D, Henley R. The stability of parathyroid hormones in blood and serum samples at 4°C and at room temperature. *Ann Clin Biochem* 1995; 32: 216-7.
 158. Sachse C, Baudach A, Tille D, Avenarius HJ, Heller S, Ruby C, et al. Multicentre evaluation of the Cobas Argos blood cell counter. *J Lab Med* 1994; 18: 441-9.
 159. Sakurai S, Shiojima I, Tanigawa T, Nakahara K. Aminoglycosides prevent and dissociate the aggregation of platelets in patients with EDTA-dependent pseudothrombocytopenia. *Br J Haem* 1997; 99: 817-823.
 160. Sanders GTB. Sample quality. *Klin Chem Mitt* 1992; 23: 11-8.
 161. Schiele F, Vincent-Viry M, Herbeth B, Visvikis A, Siest G. Effect of short- or long-term storage on human serum and recombinant apolipoprotein E concentration. *Clin Chem Lab Med* 2000; 38: 525-8.
 162. Schmitt UM, Stieber P, Pahl H, Reinmiedl J, Fateh-Moghadam A. Stabilität tumorassoziierter Antigene in Vollblut und Serum. *J Lab Med* 2000; 24: 475.
 163. Schmitt Y. Influence of preanalytical factors on the atomic absorption spectrometry determination of trace elements in biological samples. *J Trace Elem Electrolytes Health Dis* 1987; 1: 107-14.
 164. Schoenmakers CHH, Kuller T, Lindemans J, Blijenberg BG. Automated enzymatic methods for creatinine measurement with special attention to bilirubin interference. *Eur J Clin Chem Clin Biochem* 1993; 31: 861-8.
 165. Schwinger R, Antoni DH, Guder WG. Simultaneous determination of magnesium and potassium in lymphocytes, erythrocytes and thrombocytes. *J Trace Elem Electrolytes Health Dis* 1987; 1: 88-98.
 166. Seitz G, Stickel F, Fiehn W, Werle E, Simanowski UA, Seitz HK. Kohlenhydrat-defizientes Transferrin. Ein neuer, hochspezifischer Marker für chronischen Alkoholkonsum. *Dt Med Wschr* 1995; 120: 391-5.
 167. Semjonow A. PSA - unverzichtbar in der Urologie. *Diagnostica Dialog* 1994, 3: 3-4.
 168. Sharma A, Anderson K, Baker JW. Flocculation of serum lipoproteins with cyclodextrin: Application to assay of hyperlipidemic serum. *Clin Chem* 1990; 36: 529-32.
 169. Siest G, Bertrand P, Quin B, Herbeth B, Serot JM, Masana L, et al. Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: The ApoEurope study. *Clin Chem Lab Med* 2000; 38: 721-30.
 170. Simó JM, Camps J, Vilella E, Gómez F, Paul A, Joven J. Instability of lipoprotein(a) in plasma stored at -70 °C: Effects of concentration, apolipoprotein(a) genotype, and donor cardiovascular disease. *Clin Chem* 2001; 47: 1673-8.
 171. Skopp G, Klingmann A, Pötsch L, Mattern. In vitro stability of cocaine in whole blood and plasma including ecgonine as a target analyte. *Ther Drug Monit* 2001; 23: 174-81.
 172. Skopp G, Pötsch L, Klingmann A, Mattern R. Stability of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in fresh blood and plasma and post mortem blood samples. *J Anal Toxicol* 2001; 25: 2-7.
 173. Smoller BA, Kruskal, MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. *N Engl J Med* 1986; 314: 1233-5.
 174. Sölétormos G, Schiøler V, Nielsen D, Skovsgaard T, Dombernowsky P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. *Clin Chem* 1993; 39: 2077-83.

175. Sonntag O. Haemolysis as an interference factor in clinical chemistry. *J Clin Chem Clin Biochem* 1986; 24: 127-39.
176. Sonntag O, Römer M, Haeckel R. Interferences. In Haeckel R (ed). *Evaluation Methods in Laboratory Medicine*. Weinheim VCH 1993: 101-16.
177. Sonntag O, Glick MR. Serum-Index und Interferogramm – Ein neuer Weg zur Prüfung und Darstellung von Interferenzen durch Serumchromogene. *Laboratoriumsmedizin* 1989; 13: 77-82.
178. Spain MA, Wu AHB. Bilirubin interference with determination of uric acid, cholesterol, and triglycerides in commercial peroxidase-coupled assays. *Clin Chem* 1986; 32: 518-21.
179. Spence N. Differential leucocyte analysis of samples up to 48h old: improved results with citrate pyridoxalphosphate anticoagulant. *Br J Biochem Sci* 1993; 20: 645-63.
180. Stiegler H, Fischer Y, Vazque-Jiminez JF, Graf J, Filzmaier K, Fuasten B, et al. Lower cardiac troponin T and I results in heparin-plasma than serum. *Clin Chem* 2000; 46: 1338-44.
181. Szasz G, Gerhardt W, Gruber W, Bernt E. Creatinekinase in serum: 2. Interference of adenylate kinase with the assay. *Clin Chem* 1976; 22: 1806-11.
182. Tahara Y, Shima K. Kinetics of HbA_{1c}, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. *Diabetes Care* 1995; 18: 440-7.
183. Tencer J, Thysell H, Andersson K, Grubb A. Stability of albumin, protein HC, immunoglobulin G, κ -, λ -chain immunoreactivity, orosomuroid and α_1 -antitrypsin in urine stored at various conditions. *Scand J Clin Lab Invest* 1994; 54: 199-206.
184. Tencer J, Thysell H, Andersson K, Grubb a. Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain immunoreactivity, orosomuroid and alpha-1-antitrypsin in urine stored at -20°C . *Scand J Urol Nephrol* 1997; 31: 67-72.
185. Thomas L(ed.). *Clinical Laboratory Diagnosis*. Frankfurt: TH-Books, 1998.
186. Tietz NW. *Clinical Guide to Laboratory Tests*. Philadelphia: Saunders, 1995, 3rd ed.
187. Tietz NW. *Textbook of Clinical Chemistry*. Philadelphia: Saunders 1986, 1534-6.
188. Töpfer G, Funke U, Schulze M, Lutze G, Ziemer S, Siegert G. Determination of coagulation parameters in citrated venous blood, catheter blood, and capillary blood: preanalytical problems. *J Lab Med* 2000; 24: 514-20.
189. Töpfer G, Hammer T, Seifert A. Einfluß der Lagerungsbedingungen und der Lagerzeit auf die Ergebnisse der CAF-Elektrophorese mit Laktatpuffer. *Zentralbl Pharm* 1983; 122: 1045-51.
190. Töpfer G, Hornig F, Sauer K, Zawta B. Untersuchungen zur Stabilität von 11 Serumproteinen bei Bestimmung mit Immunturbidimetrie. *J Lab Med* 2000; 24: 118-25.
191. Töpfer G, Lutze G, Sauer K, Friedel G, Hornig F, Kühnert T, et al. Einfluß der Citratkonzentration in Blutentnahmeröhrchen auf hämostaseologische Meßgrößen. *J Lab Med* 2000; 24: 162-8.
192. Töpfer G, Lutze G, Schmidt LH, Friedel G, Seifert A, Novy EM, et al. Haltbarkeit des Ristocetin-Cofaktors und des Faktor VIII-assoziierten Antigens in Abhängigkeit von den Lagerungsbedingungen. *Z Med Lab Diagn* 1983; 24: 463-8.
193. Tryding N, Tufvesson C, Sonntag O. *Drug effects in clinical chemistry*. Stockholm: Apoteksbolaget AB, 1996, 7th ed.
194. Tsuji T, Masuda H, Imagawa K, Haraikawa M, Shibata K, Kono M, et al. Stability of human natriuretic peptide in blood samples. *Clin Chim Acta* 1994; 225: 171-7.
195. Uges DRA (ed.). *Orientierende Angaben zu therapeutischen und toxischen Konzentrationen von Arzneimitteln und Giften in Blut, Serum oder Urin*. DFG Mitt XV der Senatskommission für klinisch-toxikologische Analytik. Weinheim: VCH Verlagsgesellschaft, 1990.

196. Vandamme, AM, Van Laethem K, Schmit JC, van Wijngarden E, Reynders M, Debysers Z, et al. Long-term stability of human immunodeficiency virus, viral load and infectivity in whole blood. *Eur J Clin Invest* 1999; 29: 445-52.
197. Van der Woerd-de Lange JA, Guder WG, Schleicher E, Paetzke I, Schleithoff M et al. Studies on the interference by haemoglobin in the determination of bilirubin. *J Clin Chem Clin Biochem* 1983; 21: 437-43.
198. Van Lente F, Marchand A, Galen RS. Evaluation of a nephelometric assay for haptoglobin and its clinical usefulness. *Clin Chem* 1979, 25: 2007-10.
199. Verheest J, Van den Broecke E, Van Meerbeeck J, De Backer W, Blockx P, Vermeire P. Calculation of half-life of carcinoembryonic antigen after lung tumor resection. A case report. *Eur Respir J* 1991; 4: 374-6
200. Visvikis S, Schlenck, Maurice M. DNA extraction and stability for epidemiological studies. *Clin Chem Lab Med* 1998; 36: 551-5.
201. Voit R. Plasma-Serum-Unterschiede und Lagerungsstabilität klinisch-chemischer Meßgrößen bei Verwendung von Plasmatrennröhrchen. Dissertation München: Ludwig-Maximilians-Universität, 1993.
202. Wallace AM. Measurement of leptin and leptin binding in the human circulation. *Ann Clin Biochem* 2000; 37: 244-52.
203. Walne AJ, James IT, Perret D. The stability of pyridinium crosslinks in urine and serum. *Clin Chim Acta* 1995; 240: 95-7.
204. Warner A, Anneslay T. Guidelines for therapeutic drug monitoring services. *Natl Acad Clin Biochem* 1999.
205. Wilding P, Zilva JA, Wilde CE. Transport of specimens for clinical chemistry analysis. *Ann Clin Biochem* 1977; 14: 301-6.
206. Willems HPJ, Bos GMJ, Gerrits WBJ, Heijer M, Vloet S, Blom HJ. Acidic citrate stabilizes blood samples for assay of total homocysteine. *Clin Chem* 1998; 44: 342-4.
207. Wissner H. Einflußgrößen und Störgrößen. In: Greiling H, Gressner A. (eds.) *Lehrbuch der Klinischen Chemie und Pathobiochemie*, Stuttgart, New York: Schattauer, 1995; 50-71, 3rd ed.
208. Withold W. Monitoring of bone turnover. Biological, preanalytical and technical criteria in the assessment of biochemical markers. *Eur J Clin Chem Clin Biochem* 1996; 34: 785-99.
209. Witt I, Beeser H, Müller-Berghaus G. Minimalanforderungen zur Gewinnung von Citratplasma für hämostaseologische Analysen. *J Lab Med* 1995; 19: 245-7.
210. Wolthuis A, Peek D, Scholten R, Moreira P, Gawryl M, Clark T, Westerhuis L. Effect of the haemoglobin-based oxygen carrier HBOC-201 on laboratory instrumentation: Cobas Integra, Chiron blood gas analyzer 840, SysmexTM SE-9000 and BCT. *Clin Chem Lab Med* 1999; 37: 71-6.
211. Woodrum D, York L. Two-year stability of free and total PSA in frozen serum samples. *Urology* 1998; 52: 247-51.
212. Wu AHB, Laios I, Green S, Gornet TG, Wong SS, Parmley L, et al. Immunoassays for serum and urine myoglobin: myoglobin clearance assessed as a risk factor for acute renal failure. *Clin Chem* 1994; 40: 796-802.
213. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. *Clin Chem* 1994; 40: 552-61.
214. Young DS. Effects of drugs on clinical laboratory tests. Washington: AACC Press, 1995, 4th ed.
215. Young DS. Effects of preanalytical variables on clinical laboratory tests. Washington: AACC Press, 1997, 2nd ed.

216. Zhang DJ, Elswick RK, Miller WG, Baily JL. Effect of serum-clot contact time on clinical chemistry laboratory results. *Clin Chem* 1998; 44: 1325-33.

Correspondence should be addressed to:

Prof. Dr. W.G. Guder
City Hospital München-Bogenhausen
Institute for Clinical Chemistry
Engschalkinger Straße 77
D-81925 München
Fax: +49-89-9270-2113